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ABOiRTx has the potential to increase kidney donor availability and access to 
transplantation. However, precise monitoring of ABO antibodies is critical in 
guiding treatment and assessing patient suitability for ABOiRTx. 
Haemagglutination titration assay is a semi-quantitative methodology commonly 
used for measuring ABO antibodies and the amount of PE required pre- or post-
transplantation. Due to the variation in titration assays across institutions, this 
study was conducted to investigate for agreement/disagreement between these 
methods and suggest proposals for standardisation. 50 plasma samples were 
tested against the titration methods, Tube IAT, Tube DRT, Bio-Rad IAT, Bio-Rad 
DRT, Bio-Vue IAT and Bio-Vue DRT. 30 of these samples were from ABOiRTx 
patients with graft outcome data available while 20 were from ESRD patients 
awaiting transplantation. An ELISA method for the measurement of ABO IgG 
antibody subclasses (IgG1, IgG2, IgG3 and IgG4) was also developed and used to 
measure subclass levels in 9 patients. 
All titration results showed overall statistically significant difference using ANOVA 
multivariate analysis which meant that the methods cannot used interchangeably. 
However, upon pairwise analysis, association was found between the following 
pairs of methodologies: Tube IAT/Tube DRT, Tube DRT/Bio-Rad IAT and Bio-Rad 
DRT/Bio-Vue IAT. The number of PE was closely linked to baseline but not post-
transplant ABO antibody titres. The use of one operator did not improve the 
variability between the different titration methods. This suggests that all ABO 
antibody titration methodologies in current use globally cannot be used 
interchangeably, thus making it difficult to objectively manage patients pre-
transplantation. From the study results, a reasonable choice of methodology to 
propose for standardisation across transplant centres is the Bio-Rad IAT column 
method which can be developed over time and therefore provide the basis for all 
comparisons. 
Using the Indirect ELISA technique, most of the cases that experienced graft 
rejection (5/9) had a combination of IgG1 and IgG2 subclasses. No association was 
found between ABO IgG2, IgG3 and IgG4 as individual entities against graft 
outcome. IgG1 was the only antibody that demonstrated association with graft 
outcome. IgG2 was detected in 4/4 cases who did not experience graft rejection. 
IgG3 was detected in 4/5 graft rejection cases which supports its known feature of 
efficiency in activating complement. IgG4 was found in 1/9 cases, in a patient who 
experienced graft rejection. The sample size for this part of the study was too small, 
resulting in low statistical power. However, the Indirect ELISA technique developed 
in the study can be used to explore ABO IgG antibody subclass dynamics to further 
understand their role in ABOiRTx. 
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Chapter One: Introduction 
 
1.1 Overview of End Stage Renal Disease 
 
End stage renal disease (ESRD) begins when the kidneys have failed and renal 
replacement therapy is initiated. In such cases of renal impairment, the patients 
are managed through the use of haemodialysis, peritoneal dialysis or 
transplantation (1). 
ESRD significantly increases mortality and morbidity in patients and the incidence 
of this condition has doubled in the UK since 1995 and is a growing international 
problem (2). The incidence of patients with chronic (ESRD) is rapidly increasing 
worldwide as a result of an increase in patients with lifestyle associated diabetes, 
hypertension and  advancement in diagnostic methodologies (3). 
 
Most patients commencing dialysis for ESRD in low-income countries die or stop 
treatment within the first 3 months of initiating dialysis due to cost constraints. This 
is mainly because of the limited availability of haemodialysis and peritoneal 
dialysis facilities in these countries. However, kidney transplantation offers a better 
option for patients on dialysis by significantly reducing mortality and improving the 
quality and length of life for a third of the cost of haemodialysis. Although the initial 
cost of transplantation exceeds that of maintenance dialysis following 
transplantation, the subsequent cost is much reduced largely due to advances in 
cheaper immunosuppression regimens (4). As most patients would already be 
suffering from other underlying or co-morbid conditions such as hypertension or 
diabetes, undergoing transplantation procedure is taxing. 
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Due to the scarcity of organ donors, consideration has to be made for ethical and 
financial issues associated with each transplantation procedure. How long the 
graft is expected to survive and how long the patient is expected to live are both 
critical elements in the decision-making process that governs management of 
ESRD. Factors that predict graft survival have been studied extensively in adults 
and children. Donor and recipient age, pre-existing donor hypertension and 
diabetes, prolonged cold storage time, re-transplantation, multiple blood 
transfusions and body mass index of both recipient and donor have demonstrated 
to play important roles in the post-transplant outcome along with a host of other 
factors. 
 
Traditionally, ESRD patients would take a course of haemodialysis or peritoneal 
dialysis or both, possibly followed by one or more transplants. Increasingly, 
patients are opting for transplantation as the very first ESRD treatment modality, a 
choice labelled ‘pre-emptive transplant’. Much of the enthusiasm for pre-emptive 
transplantation stems from reports that they are advantageous for graft and patient 
survival. Increased time on dialysis is a predictor of negative short-term graft 
outcome and transplant recipient survival. The first successful attempt at kidney 
transplantation was in 1954 and as a result, since then, there has been an 
increase in the number of transplants being performed each year for a growing 
recipient population (5-7).  
There is evidence of improved patient and allograft survival when pre-emptive or 
early transplantation is implemented before commencement of long-term dialysis 
or within 6-12 months of initiation of dialysis.  
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Improved patient and allograft survival has been noted in cases of early 
transplantation (i.e. before commencement of long-term dialysis or within 6-12 
months of initiation of dialysis) or pre-emptive transplantation (8, 9). 
 
Advances in the field of kidney transplantation have led to an increased demand 
for donor organs which are in short supply worldwide. However, global access to 
transplantation is still limited, with Austria, USA, Croatia, Norway, Portugal and 
Spain having the greatest access and the USA, China, Brazil and India performing 
the most transplants (10). Most organs are donated from cadavers, following 
traumatic and non-traumatic brain injury. Cadaveric organs go to blood group 
matching recipients on a waiting list. Figure 1  shows that, in the UK, according to 
the Organ and Transplantation activity report 2018/19 (11), the number of 
deceased kidney donors decreased by 2% in 2018-2019 compared to the previous 
year where the number of deceased donor kidney transplants increased by 3%. 
There has been a 2% increase in the number of deceased donors. In general, 
transplants and donors have increased with time and the total number of patients 
on the transplant list has decreased as a result. 
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Figure 1 Number of deceased donors between periods 2009-2019 in the UK 
 
This increasing demand for kidney transplantation requires innovation to expand 
the pool of potential kidney donors. For example, some initiatives have been 
devised to increase the donor pool e.g. the use of the Donation after Cardiac 
Death (DCD) criteria and Donation after Brain Death (DBD) which have 
contributed in reconciling supply and demand for organ donations (12). DCD refers 
to either the retrieval of an organ after cardiac arrest that is expected and from 
which the patient cannot or should not be resuscitated or retrieval of an organ 
following planned withdrawal of life support. DBD refers to retrieval of an organ 
where brain injury is suspected to have caused irreversible loss of the capacity for 
consciousness and respiration. 
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1.2 Attitudes towards transplantation 
Ethnic minorities in different communities generally demonstrate lower donation 
rates (13). Reasons for this include lack of transplant awareness, mistrust of 
healthcare professionals and economic factors (14). In some countries, cultural 
beliefs and legal considerations amongst other factors hinder the development of 
deceased organ donation initiatives. Even in developed countries, where rates of 
deceased organ donation tend to be higher, organs obtained in this manner fail to 
satisfy the increasing patient demand. 
Countries like Japan suffer a severe shortage of cadaveric grafts as a result of 
longstanding religious beliefs and therefore more work has been undertaken to 
develop and promote living donor kidney transplants. As a result, transplants of 
this nature have been performed since 1989 (15).  
 
 
1.3  Live donor transplantation as a treatment option for ESRD 
The considerable shortage of donor organs compounded by the increasing 
number of patients with ESRD on kidney transplant waiting lists has contributed to  
long waiting times for an appropriate organ allograft (16).  
 
Most living donor transplants are ‘directed’ which means that the kidney is donated 
to a specific recipient known to the donor. However, there are several ‘non-
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When a potential living donor and recipient are biologically incompatible (blood 
group or tissue type wise) they may consider joining a list of others in the same 
situation with the hope that an exchange of kidneys between them can lead to a 
compatible living donor transplant. Between 2018 and 2019 in the UK, there were 
100 paired living kidney donor transplants (97 adults and 3 paediatric 
recipients)(11). 
 
Blood group incompatibility with regards to the ABO system has in the past been 
considered a contraindication to kidney transplantation(17) until advances in this 
area have enabled transplantation across this barrier. While kidney transplantation 
is best performed in the absence of ABO incompatibility, a large ESRD population 
and increasing organ shortage result in waiting times for deceased donor kidney 
transplant exceeding 5years in some countries such as Germany(18). Compared 
to DCD and DBD initiatives, directed or altruistic transplants cannot always be 
matched for ABO blood group compatibility. Consequently, this has led to the 
development of live donor ABO incompatible kidney transplantation (ABOiRTx) 
which is now being performed in renal centres worldwide at an increasing rate and 
has gone a long way in reducing the waiting time on transplant lists.  
 
Kidney transplantation across the ABO blood group barrier has the potential to 
expand the pool of donors, increase the availability of transplantable organs and 
decrease the time on the waiting list for a kidney. In the UK, about 30% of any 
potential unrelated live kidney and recipient pairs are ABO blood group 
incompatible and most recipients are blood group O and B. 
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The median waiting time for deceased donor kidneys in the UK is higher in these 
blood groups compared to blood group A (1381 days, 1329 days and 925 days 
respectively) (12). ABO incompatible kidney transplantation is becoming more 
commonplace as a result of improved knowledge and understanding of the 
associated immunologic mechanisms and effective immunosuppressive regimens 
(19). However, more work still needs to be done to ensure improved graft and 
recipient outcomes. ABOiRTx is further discussed in Section 1.5. 
 
1.4 The ABO blood group system 
The ABO blood group antigens remain of prime importance in transfusion 
medicine as they are the most immunogenic of all the blood group antigens. This 
blood group system is also critical in transplantation medicine as it plays a major 
role in histocompatibility. There are 4 antigens in the ABO blood group system; A, 
B, AB and H. Landsteiner, discovered blood types A, B and O (which he initially 
referred to as A,B and  C) in 1901 and his co-workers, Adriano Sturli and Alfred 
von Decastello discovered blood group AB a year later in 1902. 
 
1.4.1 Molecular basis of the ABO blood group system 
The ABO gene locus encodes specific glycosyltransferases that synthesise A and 
B antigens on red blood cells. It is located on chromosome 9 at 9q34.1-q34.2 and 
contains 7 exons that span more than 18kb of genomic DNA. Exon 7 is the largest 
and contains most of the coding sequence. Exon 6 contains the deletion that is 
found in most O alleles which results in loss of enzymatic activity. 
The A and B alleles each encode a glycosyl transferase that catalyses the final 
step in the synthesis of the A and B antigens respectively.  
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A and B determinants are oligosaccharides carried on various glycoproteins and 
glycolipids and are not primary gene products but are synthesised by the action of 
the gene-encoded glycosyltransferases. In the production of these blood group 
antigens, a sequence of oligosaccharides that are conjugated either to 
polypeptides to produce glycoproteins, or to ceramide to produce glycolipids, is 
synthesised in a stepwise manner, where a specific glycosyltransferase catalyses 
the addition of each monosaccharide.  There is a sequence of oligosaccharides 
that is common to all blood groups and is called the precursor substance (H-
substance or H antigen). The addition of terminal monosaccharides to this 
precursor substance, determines the blood group of an individual. 
 
The epitope of the H-antigen, the precursor of A, B, (and Lea and Leb) antigens of 
the ABO histo-blood groups is carried by at least 4 different core chains of internal 
carbohydrate backbones (types I, II, III and IV); the variation in these precursors 
generates antigenically distinct ABH epitopes. Localisation of ABH antigens 
carried on type I-IV chains varies among different tissues correlated with their 
embryonic and cellular differentiation (20). 
 
The addition of fucose onto the precursor substance via an α-1-2 
fucosyltransferase [FUT1] or H transferase, results in the production of the H 
antigen. This step is independent of the ABO system, but is central to subsequent 
blood group A and B production, which results from the addition of a terminal 
monosaccharide, α-D-N-acetylgalactosamine (GalNAc) in the case of blood group 
A, and α-D-galactose for blood group B.  
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The A and B genes encode specific glycosyltransferase enzymes that catalyse the 
transfer of these sugars onto the H antigen.  
For blood group O, the O gene does not produce an active transferase, with H 
substance effectively being blood group O. Fig 2 shows illustrations of the 
structures of A, B and O oligosaccharide antigens. 
 
Figure 2 Structure of A, B and O oligosaccharide antigens  
O, A and B Oligosaccharide antigens with terminal monosaccharides (Fuc, fucose; Gal, galactose and 
GalNAc, N-acetylgalactosamine) 
 
In red blood cells, the enzyme that synthesises the H antigen is encoded by the H 
gene (FUT1). In saliva and other bodily secretions, the enzyme that synthesises 
the H antigen is encoded by the Se gene (FUT2).  
 
The A/B polymorphism arises from several SNPs (Single Nucleotide 
Polymorphism) in the ABO gene which result in the A and B transferases that 
differ by 4 amino acids. As stated earlier, the O allele encodes an inactive 
glycosyltransferase that leaves the ABO antigen precursor (the H antigen) 
unmodified (21). 
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Thus, the ABH antigens are oligosaccharides which are phenotypically expressed 
as glycoproteins or glycolipids on cells and tissues and are produced through 
glycosyltransferase enzymes that progressively add monosaccharides to different 
precursor chains (22, 23). Depending on the carbohydrate moieties found on these 
precursor structures, ABH antigens can be classified as A types I-VI, B types I-VI 
and H types I-VI and at least 4 of these subtype chains have been known to carry 
ABH antigens in humans (22, 24, 25). These permutations in precursor structures 
create unique antigen epitopes (26).  
 
1.4.2 Subtypes in the ABO blood group system 
There are many variant ABO alleles that encode different variant ABO 
phenotypes, but they do not encode specific antigens other than the A and B 
antigens. For blood group A, these are often identified as the A1 or non-A1 
antigens. The A1 subgroup can be identified directly by the Dolichos biflorus seed 
lectin binding in haemagglutination assays, which is specific for the A1 antigen 
determining carbohydrate N-acetyl-D-galactosamine. The weak non-A1 
subgroups, such as A2, A3, Ax and Ael again express the A antigen and these 
subdivisions arise due to differences in both density and structure of the A antigen. 
(27, 28). About 80% of blood group A individuals are A1 which is differentiated by 
the concentration of the A antigen which is of clinical importance. Non-A1 
individuals have fewer A antigen molecules on red cells and in the kidneys. This 
decreased A antigen density is due to reduced A glycosyl transferase activity in 
non-A1 blood groups (which is about 10% relative to A1). 
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Similarly, for blood group B, the major subgroup is Group B (B1) while weaker 
subgroups such as B3 and Bx also express the B antigen but differences again 
arise due to variation in antigen density and structure and B (B1) is the main 
subgroup for Group B individuals (22, 23).  
 
In blood group AB, both A and B antigens are co-expressed, however, the 
competitive action of their respective A and B transferases, against a fixed amount 
of cell surface H antigen, leads to an overall reduction in A or B antigen density.  
 
1.4.3 General tissue distribution of ABO antigens 
In general, the ABO blood group antigens are regarded as red blood cell antigens 
but they are also expressed on other body tissues such as most epithelial and 
endothelial cells including the kidney vascular endothelium, the convoluted distal 
tubules and the collecting tubules (29). These ABO antigens in an incompatible 
graft are the target for pre-formed natural immune ABO antibodies found in the 
serum of the recipient (Section 1.4.4). This explains why hyperacute graft rejection 
(HAR) almost always occurs after ABO-incompatible kidney transplantation and 
why kidney transplantation across the ABO barrier without a prior preconditioning 
protocol (removal of ABO antibodies plus appropriate immunosuppression) is 
considered an absolute contraindication (discussed further in Section 1.5). 
 
Other blood cells, such as T-cells, B-cells and platelets, have ABO blood group 
antigens that have been absorbed from the plasma. Some individuals, called 
‘Secretors’, produce a soluble form of the ABO blood group antigens which can be 
found in saliva and all other bodily fluids apart from cerebrospinal fluid. 
 
Introduction 
Page 12 of 138 
 
1.4.4 Antibodies produced against ABO antigens 
Anti-ABO specific antibodies are not present at birth and appear following 
exposure to environmental carbohydrate antigens (30). The presence of ABO-
specific antibodies is explained according to Landsteiner’s rule i.e. they develop 
against the A or B antigen absent in the individual as shown in Table 1 below. The 
quantity of antibody present or titre increases with early childhood immune 
development. The blood group O population has higher titres than blood group A 
or B populations although there is significant overlap, and the amount of antibody 
may be affected by age and dietary intake. 
 
Table 1 Antigens and associated antibodies in the ABO blood group System 
Blood group Antigens on Red Cells Antibodies in Plasma 
A A antigen Anti-B 
B B antigen Anti-A 
O Neither A nor B Anti-A and Anti-B 
AB Both A and B antigens Neither anti-A nor anti-B 
 
ABO antibodies can be produced by 0.25% of circulating human B-lymphocytes. 
Anti-A and anti-B molecules occur as IgM, IgG, and IgA. Notably, group O 
individuals contain two separable antibodies, anti-A and anti-B and a cross-
reacting antibody called anti-A,B which is predominantly IgG (27). ABO antibody 
levels show a normal distribution between individuals, depending on age, season 
and immunising events like infections, vaccinations and pregnancies. 
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1.5 ABO incompatible Renal Transplant (ABOiRTx) 
In ABO incompatible (ABOi) transplantation, anti-A and anti-B become clinically 
significant as they bind to their respective specific antigens that are present on the 
vascular endothelia of the transplanted donor organ. The binding of these 
antibodies initiates a series of steps resulting in the loss of endothelial integrity and 
intravascular thrombosis (a process known as hyperacute rejection (HAR)). This 
process occurs within minutes of transplantation and is due to the activation of 
complement whereby complement components (C3a and C5b) acting directly or 
indirectly cause a decrease in graft function and irreversible graft loss as explained 
in section C3a has a pro-inflammatory effect, possessing chemotactic capability, 
attracting and activating granulocytes while C5b is instrumental in the formation of 
the membrane attack complex (MAC) via the recruitment of other complement 
components, C6, C7, C8 and C9. The MAC is responsible for cell lysis and 
necrosis.  
 
Complement regulatory proteins influence complement activation to protect cells 
from damage. For example, C4 binding protein is a soluble regulatory protein that 
inactivates C4b and the classical pathway convertases. Membrane cofactor 
protein (CD46) and decay-accelerating factor (CD55) are expressed on endothelial 
cells and they control activity of the classical and alternative pathway convertases. 
Antibody mediated complement activation on endothelial cells may result in the 
upregulation of the expression of membrane cofactor protein CD59 which 
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The extent of complement activation by immune complexes is determined by 
multiple factors, including the isotype of the antibody, the concentration of the 
target antigen and level of immunoglobulin, local concentration of complement 
regulatory proteins or exposure to immunosuppressive drugs which affects 
antibody production. 
 
ABO incompatible renal transplantation has long been considered a barrier to 
successful kidney transplantation. Over the last 25 years, increasing organ 
shortage necessitated research into overcoming the ABO antibody barrier. 
Currently, ABOiRTx has become a routine procedure with graft survival rates 
comparable to those of ABO compatible renal transplantation (ABOcRTx). 
Desensitisation (reduction and maintenance of the ABO antibodies to an 
acceptable level) is usually achieved by apheresis and B cell-depleting therapies 
accompanied by powerful immunosuppression (18). The A/B antibodies must be 
below a predetermined threshold at the time of the ABOiRTx and during the first 2 
weeks post-surgery. Thereafter, a rebound of the anti-A/B antibodies does not 
appear to adversely affect the kidney transplant. This phenomenon is called 
“accommodation” and is not very well understood but is discussed in more detail in 
Section 1.10. 
 
In contrast to adults, new-borns do not produce natural antibodies to ABH 
antigens, with isohaemagglutinin ontogeny generally beginning only after about 4-
6 months of age. This developmental lag allows infants the opportunity to undergo 
safe ABOiRTx without the need for aggressive therapeutic interventions usually 
required for ABOiRTx in adults or additional immunosuppressive therapies. 
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1.5.1 Brief history of ABO incompatible Renal Transplantation 
Humans have two strong transplantation antigen systems, the Human Leukocyte 
antigen (HLA) and ABO systems. In earlier studies Hume et al (17), Starzl et al 
(31) and Murray et al (32) expressed doubt regarding the feasibility of ABOiRTx. 
Although long-term survival of grafts was observed in some cases, overall 
experience indicated that hyperacute rejection (HAR) was still a possibility, 
therefore crossing the ABO barrier was generally considered an impossibility in the 
field of renal transplantation. 
 
It is speculated that the idea of depleting anti-A/B antibodies was first introduced in 
1981 following a renal transplant in a patient with major donor-recipient blood 
group incompatibility that was successfully treated for rejection through the use of 
plasmapheresis (32). In 1982 the first large study on ABOiRTx was conducted by 
Alexandre et al (33) in Belgium. They managed to achieve desensitisation through 
repeated plasmapheresis (PP), splenectomy, platelet transfusion and infusion of A 
or B trisaccharides coupled with heavy immunosuppression. Their approach 
resulted in a one-year graft survival of 75%. This development led to a wider 
utilisation and acceptance of ABOiRTx, first in Japan from the late 1980s, in the 
US from the mid-1990s and in Europe from the early 2000s (18). 
 
In another study, Capellini’s group showed that although A1 and B blood group 
skin was immediately rejected when grafted onto O recipients, blood group A2 skin 
grafts were rejected at a slower rate, comparable to O skin grafted onto O 
recipients. These findings provided a platform for attempting A2 incompatible 
kidney transplantation. 
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 In 1987 Thielke et al(34) showed that 12 out of 20 transplants from a group A2 
donors into O recipients maintained long term allograft function. The only major 
drawback is that this concept can only be used in a minority of kidney transplant 
cases owing to the low frequency of group A2 donors in most populations. 
Compared to blood group A1 and blood group B Individuals, blood group A2 
recipients make up 20% of all group A Caucasians. The low expression of blood 
group antigen molecules (30-50%) on the surface of erythrocytes in blood group 
A2 donors, is believed to be responsible for the lower immunogenicity of organs 
donated by this group (35, 36). ABOiRTx with A2 organs has been accomplished 
with basic immunosuppressive therapy without any additional measures. 
 
While, even today, kidney transplantation is best performed in the absence of 
major ABO incompatibility, the large ESRD population and an increasing organ 
shortage result in waiting times for a deceased donor kidney transplant exceeding 
5 years in some cases. Therefore, transplantation across the ABO antibody barrier 
will theoretically increase the number of kidney transplantations from living donors 
by up to 30% consequently reducing the waiting time on the transplant list. With 
currently existing protocols, as many as 90% of patients with an ABOi living donor 
may effectively be desensitised and transplanted (18). 
 
1.6 HLA and kidney transplantation 
MHC class I and II proteins are cell surface glycoproteins. Class I expression is on 
most nucleated cells, whilst Class II is restricted to predominantly B lymphocytes, 
dendritic cells and some endothelial cells, but can be upregulated in inflammatory 
responses.  
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It is the specific role of MHC Class I and Class II molecules in presenting antigenic 
peptide to the T Cell receptor (TCR) that underlies their significance as barriers to 
transplantation.  
The consequences of TCR engagement and co-stimulation are proliferation and 
differentiation of the T-cells into effector phenotypes and concomitant production 
of cytokines. The role of immunosuppression is to target signalling pathways 
responsible for T-cell activation, including TCR/CD3 engagement by the MHC, co-
stimulatory pathways such as CD28 binding by CD80/CD86 and cytokine 
signalling pathways such as IL-2 binding to the IL-2 receptor including CD25. 
 
Exposure to MHC proteins, otherwise called the HLA antigens, leads to the 
development of anti-HLA antibodies through B cell activation which requires T cell 
help. Anti-HLA antibodies are produced against both Class I and Class II proteins. 
 
1.7 Transplant/Allograft Rejection 
Allograft rejection can be hyperacute (HAR) (occurring within minutes after 
vascular anastomosis), acute (occurring days to weeks after transplantation) 
and/or chronic (occurring months to years after transplantation). Rejection can 
also be classified according to the pathophysiologic event; cellular and/or antibody 
mediated (AMR). 
 
1.7.1 Antibody-mediated renal allograft Rejection (AMR) 
Antibody mediated rejection can be hyperacute, acute or chronic as discussed in 
the sections below. 
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1.7.1.1 Hyperacute antibody mediated allograft rejection 
Hyperacute antibody mediated rejection (HAMR) is characterised by immediate 
onset of thrombosis and occlusion of graft vessels due to preformed ABO 
antibodies directed against corresponding graft tissue.  
Figure 3 shows the proposed pathogenesis of hyperacute rejection (HAR) induced 
by the binding of anti-A/B to antigens expressed on the endothelial cells of the 
ABOi graft followed by activation of the complement system. Subsequently, 
endothelial damage, inflammation and platelet aggregation can be provoked 
leading to vascular thrombosis, occlusion of blood supply and rejection. 
 
 
   Figure 3 Proposed mechanism of hyperacute rejection in ABO incompatible kidney transplantation 
Binding of anti-A/B to antigens expressed on the endothelial cells of the ABOi graft followed by activation of 
the complement system. Subsequently, endothelial damage, inflammation and platelet aggregation can be 
provoked leading to vascular thrombosis, occlusion of blood supply and rejection. (Adapted from Hur 
(2011) (37)) 
 
1.7.1.2 Acute antibody mediated rejection (AAMR) 
Acute antibody mediated rejection (AAMR) is characterised by inflammation and 
leukocyte infiltration of graft vessels and is the most common type of rejection. 
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 It can occur within weeks or months and is caused by specific recurrent antidonor 
antibodies against HLA, ABO or other antigens.   
 
AAMR presents with an acute loss of graft function after transplantation but can 
also develop years after transplantation, often triggered by a decrease in 
immunosuppression (iatrogenic, non-compliance, or malabsorption) (38). 
Alloantibodies are now considered as essential mediators of acute rejection and 
chronic rejection as discussed in Section 1.7.1.3). Alloantibodies preferentially 
attack the peritubular and glomerular capillaries in contrast to T-cells which 
characteristically infiltrate tubules and arterial endothelium thus triggering 
inflammatory and cytotoxic effects against the graft (39). 
 
Acute antibody-mediated rejection generally has a worse prognosis and requires a 
different form of therapy than the more common T-cell mediated rejection. 
Recognition of the clinical relevance of alloantibodies beyond their historical role 
as mediators of HAR has rested on a new diagnostic technique (C4d) that permits 
a definitive diagnosis of antibody-mediated rejection in a renal biopsy in the 
presence of high ABO antibody titres. C4d is a fragment of the molecule C4b, an 
activation product of the classic complement pathway (See Fig 4). Feucht et al 
(40) showed that peritubular capillary C4d deposition in renal transplant biopsies is 
strongly associated with a poor prognosis and raised the possibility that antibodies 
were responsible. C4d once formed remains in the tissue for several days after 
immunoglobulin and C1 have been released. 
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Figure 4 Complement activation pathways via the classic pathway in antibody mediated rejection 
 
Due to improvements in desensitisation and immunosuppressive protocols, the 
incidence of AAMR has markedly decreased (41). 
 
 
1.7.1.3 Chronic antibody mediated rejection (CAMR)  
The National Institutes of Health (NIH) suggested diagnostic criteria for CAMR in 
ABOiRTx (42). Specifically, at least three of the following four lesions could be 
present: arterial intimal fibrosis, interstitial fibrosis/tubular atrophy, amplification of 
glomerular basement membrane or lamination of peritubular capillary basement 
membrane. AAMR in the early post-transplant period has an adverse impact on 
long-term graft survival and contributes to the development of transplant 
glomerulopathy in chronic rejection (43, 44). 
 
The main feature of chronic graft rejection is the detection of antigens on the 
donor’s tissues as foreign entities by the recipient’s immune system.  
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However, the degree of immune reaction and thereby the degree and speed of 
graft rejection depends on the histocompatibility between donor and recipient as 
HLA matched grafts survive longer compared to HLA-mismatched grafts. The 
activation of the immune system involves 2 distinct pathways: the direct and the 
indirect pathways, as shown in Fig 5. 
 
The direct pathway involves activation of CD4+ T-cells by the donor’s antigen 
presenting cells (APCs). The indirect pathway involves the processing of the 
donor’s graft antigens by the recipient’s APCs that then activates immune cells. 
Indirect activation can stimulate the activity of activated B-cells, which then leads 
to the production of antibodies against the graft tissues. Cellular immunity has only 
a minor role to play in chronic allograft rejection. 
 
The only role T-cells play in chronic rejection is via cytokines secreted by type 2 
helper lymphocytes (Th2). Several studies have shown that cytokines secreted by 
Th2 lymphocytes e.g. IL-4, IL-5, IL-6, IL-10 and IL-13 are responsible for reactions 
such as tissue fibrosis and chronic rejection. 
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  Figure 5 Direct and indirect pathways for allograft rejection 
Adapted from (Bhatti, 2015)(45) 
 
1.8 Preconditioning/ Desensitisation for ABOiRTx 
The purpose of preconditioning/desensitisation protocols is to reduce the IgG and 
IgM antibody titres (Anti-A1 or anti-B) against the incompatible donor kidney.  
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Although there is no generally accepted desensitisation protocol for ABOiRTx, all 
commonly used strategies employ common principles as shown in Fig 6. 
 
Figure 6 Overview of desensitisation protocols for ABOiRTx.  
(a) Standard desensitisation protocol (b) Another example of desensitisation protocol. IA, Immunoadsorption; 
IVIg, Intravenous immunoglobulin; PP, plasmapheresis 
 
 
These include, together with a powerful maintenance immunosuppression one or 
more of the following: 
 Anti-A/B antibody depletion at the time of transplantation using 
Plasmapheresis, double filtration Plasmapheresis/membrane filtration or 
selective or unselective immunoadsorption (IA). 
 Modulation of the recipient’s immune system using intravenous 
immunoglobulins (IVIgs) 
 Reduction of the B lymphocyte pool by splenectomy, or more recently by the 
anti-CD20 antibody rituximab. 
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 Prevention of the deleterious consequences of complement activation upon 
anti-A/B antibody binding to the graft endothelium (18). 
 
The main purpose of desensitisation protocols is to ensure depletion and 
maintenance of anti-A/B antibodies in the immediate 2 weeks post transplantation 
period below a predetermined threshold that is considered safe. After this period, 
despite a rebound of anti-A/B antibodies at high levels, they do not cause damage 
to the transplant; a phenomenon called “accommodation” (18) -this is described in 
more detail in Section 1.10. 
 
For transplant accommodation to occur, the offending ABO antibody has to be 
removed, and this can be achieved through use of techniques such as therapeutic 
plasma exchange (TPE), double filtration plasmapheresis (DFPP) and antigen 
specific immunoadsorption (IA) (46). These techniques are discussed in more 
detail in the following sections. However, there have been no clinical trials to 
evaluate the efficacy of antibody depletion procedures or a standardised 
monitoring protocol thus making it difficult to draw any conclusion on the 
relationship between these methods and their respective clinical outcomes (47). 
Alexandre et al (33) introduced an effective desensitisation protocol to achieve 
success in ABOiRTx. This protocol included pre-transplant repeated plasma 
exchange (PE) as a strategy to reduce the titres of anti-A and anti-B antibodies. A 
one-year graft survival of 75 % and a recipient survival of 88% were achieved in 
the 23 recipients (48). Due to the success of their protocol, it became the basis of 
the next desensitisation protocols for ABOiRTx. 
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These efforts were expanded in Japan because of the near absence of deceased 
donors and the only 0.15% of living A2 donors. In addition, the largest number of 
ABOiRTx since 1989, more than 1000 cases, has been performed in Japan (49). 
The percentage of ABOiRTx surgeries reached 14% of all living donor kidney 
transplants performed in Japan (34). Following the remarkable results reported in 
the Japanese centre utilising modern desensitisation techniques, together with the 
development of new immunosuppressive therapies, ABOiRTx began receiving 
new interest in Europe and the USA in the early 2000s (46). 
 
Currently, there are many different induction immunosuppression regimens in HLA 
incompatible transplants (HLAiRTx) and ABOiRTx, using a variety of different 
approaches. No randomised controlled trials have been conducted to compare 
regimens in detail and as a result no recommendations have yet been made 
concerning the details of induction therapy. The table below summarises some of 
the most commonly used desensitisation modalities and a brief description of their 
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Table 2 Prevention and treatment modalities for antibody mediated rejection 
I= Inhibition and depletion of antibody-producing cells 
II= Removal or blocking of pre-existing or newly developed antibodies 
 (Adapted from Cai and Terasai  2005)(50) 
 
1.8.1 Therapeutic plasma exchange 
Therapeutic plasma exchange (TPE) is the most common, cheapest and simplest 
method for plasma antibody depletion (46). It also known as plasmapheresis (PP) 
and in this procedure, large volumes of patient’s plasma are removed from the 
patient through filters and centrifugation and discarded but replaced with the same 
volume of colloid solutions such as human albumin solution (HAS) and/or fresh 
frozen plasma for regulation of haemodynamics (51-53). TPE is often used in 
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TPE is widely used to reduce antibody levels to predetermined acceptable levels 
both pre- and post-transplantation (55-57). 
 While TPE temporarily removes approximately 20% of the anti-ABO antibodies 
per session, it is not adequately selective and thus removes protective antibodies, 
coagulation factors (I, II, V, VII and X), antiviral and antibacterial immunoglobulin G 
(IgG) and Immunoglobulin M (IgM). This non-selectivity results in an increased risk 
of bleeding and/or infection (58). The number of TPE sessions required per patient 
depends on the initial antibody level/titre, the dynamics of antibody rebound and 
the clinical condition of the patient. On average it can take up to 2-8 exchanges to 
reduce the ABO antibody titres to the required level and this can take up to a 
fortnight. 
 
1.8.2 Immunoadsorption (IA) columns 
The selective technique of antigen-specific immunoadsorption (IA) is safe and 
more effective. Using IA, the plasma is processed through a Glycosorb ABO 
immunosorbent column, which selectively removes the ABO antibodies, and is 
then re-infused into the patient. No coagulation factors are removed with this 
technique and it allows for large volumes to be processed and no plasma volume 
discarded, thus making this technique more efficient than TPE (46). Since this 
technique does not affect the resultant plasma volume, there is no limit to the 
number of adsorption cycles (51). 
1.8.2.1 Staphylococcal protein A column (SpA) 
The Staphylococcal Protein A (SpA) is a protein found in the bacterial cell wall of 
Staphylococcus aureus and binds to most mammalian IgG with variable efficiency, 
by forming a strong bond with the Fc fragment of IgG subclasses (Subclasses 1, 2 
and 4) and a less strong one with IgG3, IgM and IgA (59). 
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In ABOiRTx, SpA columns are used to remove anti-A and anti-B antibodies where 
patients undergo three or four sessions of IA until their anti-A IgG/IgM titres fall to 
the required levels (54).  However, the use of SpA columns to remove antibody 
has been superseded by TPE which is widely accessible in most transplant 
centres.  
 
1.8.2.2 Glycosorb columns 
The protocol developed by Tyden and colleagues (60) introduced A/B antigen-
specific antibody removal, in combination with rituximab therapy. They devised 
A/B antigen-specific antibody removal columns i.e. Glycosorb® ABO (Glycorex, 
Sweden). This involved the conjugation of A and B trisaccharides to Sepharose 
beads packed in a column. Plasma is then passed through these columns thus 
allowing for selective removal of ABO antibodies while leaving coagulation factors, 
complement, other immunoglobulins and albumin (61). Despite the ability of 
Glycosorb columns to selectively remove ABO antibodies, they also remove other 
anticarbohydrate antibodies, i.e. against Pneumococcus and Haemophilus, 
however, protein based immunity remains intact (62). The concept of the 
Glycosorb columns has recently been utilised in developing a pan-immunoglobulin 
technique that allows for concurrent removal of anti-ABO and anti-HLA antibodies. 
In this version of IA, sheep anti-human antibodies are used to remove human 
immunoglobulin while allowing for antibody elution and re-use of columns unlike 
conventional Glycosorb columns. 
 
1.8.3 Splenectomy  
The spleen is a multifunctional organ that produces lymphocytes, filters blood, 
stores red cells and removes those that are ageing.  
Introduction 
Page 29 of 138 
 
Performing splenectomy (removal of the spleen) in ABOiRTx recipients effectively 
removes a major site of functional maturation of lymphocytes, including antibody 
secreting B-cells, as the spleen plays a role in the production of anti-A and anti-B 
antibodies through B cells. However, splenectomy does not remove all antibodies 
as some will still be in circulation.  
 
In the past, splenectomy was a necessity for the desensitisation protocol for 
ABOiRTx, due to its contribution in the reduction of the antibody producing B-cell 
pool (19). Splenectomy was replaced with rituximab (anti-CD20) monoclonal 
antibody for B-cell depletion – See Section 1.8.5.1 for a discussion on rituximab 
(19, 48).The effectiveness of splenectomy in ABOiRTx has not been unequivocally 
proven. For example, Sonnenday et al (48) did not find any significant difference in 
anti-ABO antibody levels post splenectomy between splenectomised and non-
splenectomised patients. Gloor et al (63) also stated that splenectomy was not 
necessary even for patients with high baseline anti-ABO antibody titres. Takahashi 
(64) demonstrated that, due to splenectomy, significant numbers of memory B-
cells exist in the bone marrow, splenectomy is not necessary to inhibit antibody 
production. Therefore, there is now a growing consensus that splenectomy in not 
necessary in ABOiRTx recipients (44).  
 
The main drawback of splenectomy is that it associated with complications of 
immunodeficiency in children and the elderly who are susceptible to Streptococcus 
pneumoniae and Haemophilus influenzae infections (65). Several transplant 
centres have therefore developed protocols without splenectomy, which include 
antigen specific IA, rituximab and other immunosuppressive drugs. 
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1.8.4 Allograft Modification 
A futuristic innovation that may be introduced involves the reduction of blood group 
antigen levels in the allograft by ex vivo infusion of endo-beta-galactosidase 
(Abase) (66). Recombinant endo-beta-galactosidase (ABase) releases A/B 
antigen and was produced in E. Coli BL-21.  
 
This innovation is based on a study whereby Human A/B red cells were mixed with 
ABase and then subjected to flow cytometric analysis after incubation with human 
sera. ABase recovered 82% of A antigen and 95% of B antigen in human A/B red 
cells and suppressed anti-A/B antibody binding and complement activation 
effectively. Ex vivo perfusion of excised baboon kidney (group B) with ABase 
resulted in the reduction of B antigen expression in glomeruli to 6% after 4 hours 
(66). This development has created a possibility for the ex vivo removal of A and B 
antigens before kidney ABOiRTx and this might pave the way for removal of the 
requirement for antibody reduction and immunosuppressive protocols. 
 
1.8.5 Immunosuppressive regimens 
 
There are slight differences in preconditioning formalities, depending on the 
transplant centre, in order to ensure transplant success. Despite these differences, 
most use a combination of pre-transplant TPE, intravenous immunoglobulin (IVIg) 
and tacrolimus-mycophenolate-based immunosuppression. Splenectomy or 
rituximab (anti-CD20) administration is used selectively. 
 Close monitoring of the anti-ABO antibody titre is undertaken for a minimum of 
two weeks post ABOiRTx and, if necessary, TPE is performed in order to prevent 
or minimise any antibody rebound (19, 67).  
Introduction 
Page 31 of 138 
 
 
1.8.5.1 Anti-CD20 Monoclonal antibody (Rituximab) 
As a major limitation of splenectomy is suppressed immunity against certain 
pathogens, the anti-CD20 monoclonal antibody, Rituximab has now replaced this 
procedure.  
 
This drug directly inhibits B-cell proliferation and induces cellular apoptosis 
through the binding of complement which then mediates antibody dependent cell-
mediated cytotoxicity and subsequent cell death (68). Rituximab is generally 
considered as a form of “chemical splenectomy” because of its ability to deplete 
the B-cell compartment (69). The main advantage of Rituximab over splenectomy 
is that it removes the B-cell during the period where there is greatest risk of AMR 
and thereafter allows restoration of the humoral immune system without the need 
to remove the spleen (70). Fuchinoue et al (71) reported that patients who 
received Rituximab induction had a lower incidence of AMR and better outcome of 
5-year graft survival compared to those in ABOcRTx or ABOiRTx recipients who 
were not treated with Rituximab. 
 
1.8.5.2 Intravenous immunoglobulins 
Intravenous immunoglobulins (IVIg) are administered by some transplant teams 
before ABOiRTx to prevent the anti-A/B antibody rebound in the immediate phase 
after transplantation. IVIg infusion is also thought to reduce complications due to 
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It is important to note that IVIg preparations contain IgG antibodies directed 
against A/B antigens and can falsely increase anti-A/B antibody titres thus 
confounding the interpretation and consequently wrongly influencing clinical 
decision making (72, 73).  
Therefore, it is important that all clinical details are collected before undertaking 
ABO antibody titrations in order to take into account factors that can influence the 
results.  
 
1.9 Acceptable anti-blood group antibody titre at time of transplantation 
Since the removal of anti-ABO antibodies is crucial to the success of the 
transplant, optimal target levels of these antibodies need to be established for 
prophylactic purposes against AMR. Figure 7 below shows the impact of anti-ABO 
antibody starting titres on AMR.  
 
Figure 7 Impact of anti-A/B antibody starting titre on active antibody-mediated rejection episodes 
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Before the initiation of preconditioning, the baseline anti-ABO antibody titre is well 
established as a significant predictor of the severity of AMR as well as graft 
survival (44, 74). 
 
From the data shown in Fig 7, it can be postulated that an anti-ABO antibody titre 
of both IgG and IgM class >32 just before transplant is a strong predictor of AMR. 
 
Therefore, in general it can be subjectively suggested that desensitisation is 
necessary to reduce anti-ABO blood antibodies to a titre of ≤16. The subjectivity of 
the suggestion stems from the differences in immunosuppressive regimens used 
and antibody titration methodologies by each transplantation team.  
 
The titre level at which a renal transplantation can safely be performed has not 
been unequivocally established. Welsh et al (75) claimed that in their study, the 
results were better if a titre <64 (in A2 to O cases) was reached. Other authors aim 
at titre levels ≤ 16 in major (A1 and B cases)(76). Some institutions use the 
antiglobulin IgG antibody titre endpoint as the critical titre when assessing patients 
before and after transplantation. Others consider both IgM and IgG antibody titres 
(47).  
 
Antibody reduction in ABOiRTx is regarded as the key to improving outcomes, in 
patients at high risk of both hyperacute and acute rejection. The target titre levels 
of equal to or less than 8 on the day of transplant have been shown to improve 
outcomes (77).  
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The importance of lowering antibody titres to less than 8 to prevent negative 
outcomes with higher anti-graft antibodies is logical as early clinical outcomes in 
Japan showed that higher pre-operative IgG levels were associated with worse 
clinical outcomes both in graft survival and humoral rejection (78). 
Early rejection of transplanted kidneys is most likely to be humoral, involving 
antibody binding to renal vascular endothelium. This antibody-mediated process 
may not initially be accompanied by elevated antibody levels as adsorption of 
antibodies in the kidney may keep levels constant, until saturation of the binding 
sites leads to antibody titre levels rising. Antibody titres of greater than 128 have 
been successfully transplanted with post-transplantation titres of 16 being 
maintained, without antibody-mediated rejection occurring (79).This might mean 
that pre-transplantation ABO antibody titres might not be as important if levels are 
reduced post- transplant through plasma exchange and immunosuppression. 
 
1.10 Accommodation 
The presence of alloantibody is usually associated with tissue injury, however, not 
all allografts are adversely affected despite the presence of alloantibody. This 
phenomenon is called “accommodation” and was first described in animal models 
of xenotransplantation when xenograft loss was not observed despite the  
presence of anti-donor antibody (80). Accommodation was first described in 
human ABOiRTx whereby biopsies of functionally healthy grafts showed 
persistence of ABO antigens on endothelial surfaces (81, 82) despite the presence 
of anti-ABO antibodies. This discovery inspired the idea that a different antibody 
and ABO antigen interaction with no concurrent graft injury existed.  
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In order to understand the process of accommodation, molecular markers of 
immunological injury/activation are now being used to demonstrate activation of 
the immune system, despite good allograft function and no chronic histological 
injury in light microscopy. With the accumulation of evidence showing 
immunological activity against the graft, it can therefore be hypothesised that 
accommodation may represent a dynamic process of slow graft rejection resulting 
in either immunological tolerance or graft injury.  
 
Park et al (83) defined the criteria of accommodation in ABOiRTx to include (a) 
detectable anti-ABO antibody in the recipient’s serum, (b) normal graft histology 
according to light microscopy, (c) the presence of A or B antigen in the graft and 
(d) renal function similar to that of ABO compatible patients (GFR greater than 
45mL/min at 1 year after transplant).  In 2006, the American Society of 
Transplantation also established that accommodation occurred when complement 
component (C4d) deposition was detected with normal function and structure of 
graft (84). 
 
1.10.1 Mechanism of accommodation 
A few mechanisms have been proposed to explain accommodation. These include 
reduction in antigen-antibody interaction due changes in function of anti-donor 
antibody or graft antigen, difference in antigen expression, decreased 
susceptibility of injury to endothelium and complement components, acquired 
resistance of allograft through the expression of an anti-apoptotic gene or an 
expression of complement regulatory protein(s).  
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Ishida et al (41) demonstrated that functional or structural changes in anti-blood 
type antibodies greatly contributed to successful accommodation after ABOiRTx. 
They showed that anti-A antibody showed strong binding activity against donor 
erythrocyte membranes pre-accommodation, but this activity was suppressed 
once accommodation was established. In addition, the presence of diffuse C4d in 
the absence of capillary endothelial damage or inflammation suggests that 
accommodation may be due to resistance to the terminal effectual part of the 
complement cascade in ABOiRTx (39). Another concept was introduced by 
Griesemer et al (84) suggesting that upregulation of a complement regulatory 
protein such as CD59 may be involved in accommodation through interference 
with the formation of the membrane attack complex (MAC) on the accommodated 
graft.  
 
Kirk et al (85) suggested that accommodation is due to a switch between the IgG 
subclasses to favour the IgG2 subclass that is less effective at activating 
complement and that competitively inhibits the binding of the more cytotoxic 
subclasses.  
 
Park et al (83), Delikouras and Dorling (86) discovered that the Bcl and Bcl-xl anti-
apoptotic molecules were found in the accommodated ABO incompatible kidney 
graft. Conversely, Bax, a pro-apoptotic marker, was not detected. Salama et al 




Page 37 of 138 
 
This evidence seems to support the hypothesis that the initial exposure of the 
endothelium of the kidney allograft to low levels of anti-ABO antibody will trigger 
series of protective changes in the graft that manifest thus effecting 
accommodation. 
 
1.11 Antibody rebound post transplantation 
The association between antibody levels and graft function has not been clearly 
demonstrated. For example, good graft function has been observed despite ABO 
antibody titres of up to 256 (13). The key to clinical outcome seems to be the 
transplanted graft rather than the presence of antibody.  
 
1.12 Clinical outcomes in ABOiRTx   
Single centres report good outcomes for patients receiving ABOiRTx, equivalent to 
ABOcRTx cohorts within centre. This comparability between ABOiRTx and 
ABOcRTx could be attributed to advances in desensitisation techniques resulting 
in improved graft survival rates (18). Fig 8 shows cumulative incidence of death 
censored graft survival compared to patient survival in recipients of ABOiRTx. 
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Figure 8 Cumulative incidence of (A) death censored graft survival and (B) patient survival in recipients of an 
ABO-incompatible living donor graft and matched controls receiving an ABO-compatible living donor graft(18) 
 
Gernberg et al (88) reported that ABOiRTx had no negative impact on long-term 
graft function compared to that of ABOcRTx in terms of patient survival, graft 
survival or incidence of acute rejection after a mean follow-up of three years.   
Tanabe (69), summarised the outcomes of 851 ABOiRTx performed in 82 
institutions in Japan between 1989 and 2005. The five-year graft survival in their 
study was 79% with patient survival at 90%. Fuchinoue et al (71) , reported the 
five-year outcome of ABOiRTx as a graft survival rate of 100% whereas Ishida et 
al (49), achieved a graft survival of 57% and patient survival of 89% at ten years 
postoperatively for more than 130 cases of ABOiRTx.  
 
In the analysed United Network for Organ Sharing (UNOS) data of Gloor and 
Stegall (2007)(44), they concluded that a long-term immunological response 
against ABO incompatibility had little effect on graft survival with current 
immunosuppressive protocols and patient monitoring.  
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For instance, in the study of Tyden et al (60), recipients with a baseline anti-A or -
B IgG titre of up to 1:128 were successfully transplanted with no episode of acute 
rejection. Montgomery (67) reported one-year patient and graft survivals of 96.3% 
and 98.3% respectively, in a cohort of 60 consecutive ABOiRTxs using a variety of 
protocols. Oettl et al (89) demonstrated a 100% survival rate of both patients and 
grafts at one-year after transplant.  
 
1.13 ABOiRTx and infection 
A higher frequency of viral infections such as Cytomegalovirus (CMV), Herpes 
Simplex Virus (HSV), Varicella Zoster Virus (VZV) and BK virus as well as P. 
jirovecii pneumonia, wound and severe urinary tract infections have been 
described in ABOiRTx patients (90, 91). A higher incidence of BK virus replication 
and BK virus associated nephropathy was also observed by Becker et al (92).  
Bentall et al (93) hypothesised that different blood group antigens may influence 
binding of viral pathogen receptors to sialic acid on renal tubular cells.  
For example, it is thought that ABOiRTx recipients may be more susceptible to BK 
virus allograft nephropathy compared to HLA incompatible recipients even though 
HLA incompatible recipients have the most immunosuppression (94). Infections 
and other comorbid conditions may affect the survival of the graft and the recipient 
and this will affect survival analysis data.  
 
1.14 Cost-benefit analysis of ABOiRTx 
As ABOiRTx requires protocols for antibody reduction and immunosuppression 
which require utilisation of resources. The cost of ABOiRTx also includes the 
surgical procedure, cumulative total length of hospital stay and total number of 
pre- and post-operative hospital visits. 
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 Therefore, the justification for ABOiRTx in the National Health Service (UK) is 
based upon both clinical and cost effectiveness. 
A review of standard transplantation revealed that it is cost effective by a margin of 
about £15000 per annum over a 10-year period. A meta-analysis of papers 
published between 1968 and 1998 indicate a cost saving of US$55000-80000 per 
life year by each centre in haemodialysis, compared to a cost of US$10,000 per 
life year saved by transplantation. Overall, this yields a cost saving for 
transplantation of US$45000-70000 per patient per year (13). 
 
The Mayo Clinic, USA, estimated that ABOiRTx was approximately US$38000 
more expensive than ABOcRTx, but the cost effectiveness was realised 
overtime(95).  
 
Transplantation is not only beneficial for the individual but also represents value to 
the greater health economy. The first year of care after a kidney transplant costs 
around £17000 and £5000 for every subsequent year, whereas the average cost 
of dialysis is £30800 (96). After transplantation, many patients can return to work 
and therefore become less dependent on state support. 
 
1.15 ABO antibody measurement 
Despite good outcome data achieved in most centres, the need to provide reliable 
care through accurate and reproducible titre levels continues to be a goal that 
remains to be achieved. The number of plasmapheresis cycles is based on 
accurate antibody measurement, and this has an impact on patients, staffing and 
ultimately the cost of the process of transplantation (95, 97).  
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Antibody measurement after a clinical event such as graft rejection does not 
adequately benefit clinical management compared to that which can predict the 
risk of the clinical event in order to pre-emptively guide patient management. 
 
Currently several methods for this purpose exist and they include: Titration (by 
either column or tube techniques) , Flow Cytometry, Enzyme Linked 
Immunosorbent Assay (ELISA)(98)  and  Surface Plasmon Resonance (SPR) (99).   
SPR is a platform that allows molecular interactions (antibody- antigen binding 
affinities) to be assessed as association and dissociation constants. This is a 
concept that looks not at the quantity of antibody but rather the quality of antibody 
in terms of binding and hence can be used to investigate anti-ABO specific 
antibody binding to A/B antigens. 
 
Of all these methods, ‘titration’ meets most of the attributes of the ideal method i.e. 
it is simple to perform, already in routine use, cheap and fast. Krishnan et al (100)   
demonstrated correlation between flow cytometry and haemagglutination titre in 
clinical cases with anti-ABO specific antibody and monitored changes in levels 
over time in response to clinical therapies. Although flow cytometry has been 
known as a more sensitive method than agglutination for antibody detection such 
as HLA antibodies, however, there is not much evidence to support its use in 
measuring ABO antibodies(101). 
 
Development of all these methods will assist in the formulation of reliable and 
reproducible assays to measure anti-ABO antibodies.  
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Improved reproducibility of anti-ABO antibody measurement is an important step 
towards: 
 Prospective studies across centres comparing various desensitisation 
protocols including TPE and immunosuppression. This will subsequently allow 
for more meaningful meta-analytical inferences as antibody measurement 
methodology will no longer be considered a variable due to standardisation. 
 
 Risk stratification based upon antibody quantification, i.e. the ability to identify 
patients likely to develop early allograft loss or AMR who may be offered 
alternative treatment strategies such as paired exchange/kidney swap with 
another donor. 
It may also be possible to differentiate antibodies on the basis of isotype, subclass 
or other characteristics associated with likelihood to cause organ damage. This is 
covered in Section 1.16. 
 
1.15.1 ABO antibody titration (Haemagglutination Assay) 
While anti-HLA antibody measurement has progressed overtime, the 
measurement of anti-ABO specific antibodies is still largely based on a technique 
reported by Landsteiner over 100 years ago. This haemagglutination technique is 
a serial doubling dilution of patient’s plasma until no reaction is obtained against 
cells with the corresponding antigen. The titre is then defined as the inverse of the 
last dilution to give a positive reaction. There are different variations of this 
technique, but all are based on the same principle of the last serial dilution to give 
a positive reaction. 
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However, not only are the conditions at which reactivity is assessed different 
between laboratories, but the ability to reproduce them precisely has also been 
recognised as problematic. For example, it has been the practice for a long time to 
save a sample to be retested alongside a subsequent one to ensure that an 
apparent change in strength was not due to different application of the technique. 
While such duplicate testing mitigates the problem of imprecision within the 
laboratory, variation in technique makes application of uniform guidelines 
problematic across laboratories and time and contributes to the difficulty in 
predicting the clinical impact of antibody strength. 
 
An ideal anti-A or anti-B titre before ABOiRTx is defined differently dependent on 
the centre and, to further compound this issue, the titration methods vary across 
different centres. As a result, interventions to allow for ABOiRTxs to be successful 
vary widely resulting in some patients being over- or underprepared. 
 
 Data from an exploratory exercise carried out by UK NEQAS (102-104), showed a 
wide variation in practice and consequent variation in antibody levels (titres) 
obtained even when the same technology was used on the same set of samples.  
Bentall et al (105) on behalf of UK NEQAS ABO titration group reported results of 
a survey of 14 UK centres undertaking ABOi transplantation and the median IgG 
haemagglutination titres that clinicians would accept patients onto the ABOi 
program for treatment was 512 (range, 128-4096). The median target for 
acceptable titre on the day of transplantation was 8 (range, 2-16).  
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These centres had up to 5 dilution titre difference when comparing in-house 
techniques in the respective laboratories which was reduced to 1 dilution 
difference when a reference technique was used. The variation in results across 
the centres is shown in Fig 9. 
 
 
Figure 9 A comparison of reference and in-house Indirect Agglutination technique (left) and Direct Agglutination room 
temperature technique (DRT) (right) 
 
This demonstrates a need to standardise methodology and formulate national 
guidelines for ABO titrations. The non-standardisation of titration protocols causes 
problems where titration results are shared between transplant centres for 
decision making. Several other surveys and studies have shown the differences in 
detailed protocols and results (102-104, 106).  This implies that a technique for 
determination of ABO antibodies must be available and must be ideally simple to 
perform, readily available, cheap, fast reliable and reproducible.  
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In terms of ABO antibodies, “titre” is defined as the maximum dilution of the 
patient’s plasma (which contains either anti-A and/or anti-B) causing agglutination 
with a defined suspension of A1 or B cells (29).  
 
Most laboratories perform ABO antibody titration by a haemagglutination 
technique, and it is known that that this method is not perfect, with considerable 
inter-and intra-laboratory variation, although there is a degree of standardisation 
with gel-card based haemagglutination assays (107). This makes it hard to define 
an upper limit of antibody level at which transplantation is high risk. Although it can 
occur with any pre-transplant level, AMR is more likely when the ABO titre is 
greater than 256 (108, 109).  
 
1.15.2 Standardisation of ABO antibody titration 
Antibody titration is difficult to standardise due to several factors as discussed in 
the following section. Several surveys have been undertaken to understand and 
solve the problem of differences in titration protocols to enable comparison 
between different centres or studies. In these studies, the main sources of method 
variation included (76): 
 Different technologies (e.g. tube or column methods) 
 Differences in the definition and visual interpretation of the titration endpoint 
 Different reagents used e.g. type of diluent, Coomb’s reagent and test red cells  
 Use of plasma or serum 
 Use of different Incubation times 
 Reagent cells used (Commercial or Donor) 
 Repeated Freezing and thawing of sample  
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 Absence of a reference standard 
The presence of so many sources of variation makes standardisation difficult to 
achieve as all the differences must be reconciled and a consensus reached on a 
specific detailed method for either column or tube methods.  
The final method chosen should provide minimal susceptibility to technical 
(reagents and equipment) and subjective (human judgement) influence. These 
factors are described in more detail in the following sections. 
 
1.15.3 Use of controls 
Currently there are no standard controls that can be used to monitor the precision 
of titration methods. The parallel use of a frozen aliquot of a previously run sample 
during each titration may prove beneficial in providing an internal reference against 
which the current procedure could be referenced (106). This represents an internal 
control to ensure reproducibility of results but may not be ideal for reducing inter-
laboratory variability of titrations unless the same control is used across all 
institutions. The sensitivity of this technique in detecting procedural variability 
would need to be determined on larger scale as there have not been any studies 
conducted to that effect. In addition, repeated freezing and thawing of the control 
may introduce error by affecting antibody activity but this can be circumvented by 
aliquoting the control to avoid refreezing. 
 
 It may be necessary to establish an international standard (definitive control) 
against which each laboratory carrying out its chosen method of titration will 
rationalise or standardise their result to cater for the variation across institutions. 
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 A regular quality control survey may be necessary to improve the accuracy of 
titration; however, standardisation of anti-A/B antibody titration is essential before 
this can be done. 
 
1.15.4 Titration endpoint and grading reactions 
The titration endpoint is defined as the last dilution of plasma to give a positive 
reaction with a given reagent cell. This begs the question, “What reaction grade 
should be considered as positive?” since titration involves visual interpretation 
which is prone to subjectivity. Reproducible grading is well known to be 
problematic even among staff in the same laboratory. The difference between a 1+ 
and a 2+ grading may be less discernible to some individuals than that between a 
weak (W+) and a 1+. The effect of such differences in judgement was 
demonstrated by Aubuchon et al (106) who showed that inter-laboratory variation 
of titration results may be reduced by using a weaker end-point grading (W+) 
instead of the usual 1+. Therefore, there should be a consensus on the grading of 
the titration endpoint and perhaps a more objective way of reading the endpoint 
should be devised to reduce inter-observer variability. 
 
 
Before initiation of preconditioning, the baseline anti-ABO antibody titre is well 
known as a significant predictor of the severity of antibody-mediated graft injury as 
well as graft survival. Although a few recent reports have shown that a high 
baseline antibody titre is no longer predictive of poor graft outcome in patients that 
received tacrolimus- or mycophenolate mofetil-based immunosuppression, 
antibody removal should be as complete as possible (110). 
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Different groups use the antiglobulin IgG antibody titre endpoint when performing 
the pre- and post-transplant assessments. Others consider both IgM and IgG 
titres. It is also uncertain which isotype of anti-ABO antibody between IgM and 
IgG, is associated with antibody mediated graft damage (111). 
 
1.15.5 Reagent red cells used 
Given the extent of variability in antibody titration techniques, it is necessary to use 
the same method for consistency between different centres. This would mean 
using the same reagents (e.g., test red blood cells) and conditions (like incubation 
temperature and centrifugation speed). However, it is impossible to use the same 
test/reagent red cells worldwide due to logistical problems, therefore, it has been 
suggested that kidney donor red blood cells (i.e. red cells from the respective 
kidney donor) be used as test red cells for A/B antibody titration in ABO-
incompatible kidney transplantation (51). This is based on the assumption that 
expression of ABO antigens on the red cells is similar to the expression in the 
ABO-incompatible organ to be transplanted.  
However, there is no absolute correlation between ABO antigen expression on red 
blood cells and in kidneys (76).  
 
In the current study, commercial red cells, supplied by the National Blood Service 
will be used as they are readily available for other purposes in our laboratory and 
inter-batch variability can be monitored whenever new batches are supplied to 
exclude the “type of reagent red cells” used as a variable. 
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1.15.6 Absence of a reference standard 
The classical diagnostic accuracy paradigm involves a comparison of the results of 
the test under evaluation (index test) with the results of the reference/gold 
standard (i.e. the best available method to determine the presence or absence of 
the condition or disease of interest). Accuracy measures agreement of test under 
evaluation with the outcome of the reference standard. In our study, there is no 
acceptable reference standard as all methods to be investigated are in routine use 
worldwide regardless of their differences. In the absence of an acceptable gold 
standard, application of the accuracy paradigm becomes impossible as there is 
nothing to compare the methods against. 
 
Antibody titres are conventionally measured against reagent cells of donor ABO 
type and not against donor red cells, and IgG levels, rather than IgM levels are 
important in terms of defining risk of failure. There are differences in the methods 
for measuring anti-A and anti-B antibodies that may make comparison from 
different studies and countries difficult. Titres lack absolute precision so, even with 
a similar method, significantly different titre levels can be obtained. This is 
supported by a comparative study performed in 3 centres in Sweden and Germany 
that showed that, even though laboratories used the same methods, there were 
considerable differences between the results obtained in different laboratories 
where the same sample differed by a median of 3 (range 0-6) titre steps using gel 
and tube techniques (112). 
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1.15.7 External quality assurance scheme 
Whichever method is used to measure ABO antibody levels, it is recommended 
that there is regular quality control of the method, for example the National 
External Quality Assurance Scheme (NEQAS) for Blood Transfusion Laboratory 
practice allows for the comparison of results obtained in different laboratories (13). 
This will allow individual laboratories to compare their results with other 
laboratories to assess for consensus and therefore formulate the basis for 
introducing internal adjustments until results are comparable.  
 
1.16 Antibody subclasses in ABOiRTx 
1.16.1 Significance of ABO IgG subclasses in renal transplantation 
IgG is the most common antibody isotype in humans and it exists as IgG1, IgG2, 
IgG3, IgG4 subclasses which are robustly stable. The differences between the 
subclasses are mainly in the constant regions especially in the hinges and upper 
CH2 domains. These are the parts that are involved in binding to IgG-Fc receptors 
(FcγR) and complement CR1.  
The basic structure of all immunoglobulin molecules is a unit of 2 identical light (L) 
polypeptide chains and 2 identical heavy (H) polypeptide chains linked together by 
disulphide bonds. The class and subclass of an immunoglobulin is determined by 
its heavy chain type.  
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Figure 10 Schematic layout of IgG subclasses  
(Adapted from Vidarsson et al 2014) (115) 
 
Figure 10 shows how the heavy and light chains are linked, the length of the hinge 
and the number of disulphide bridges connecting the heavy chains. These 
properties result in the differential effector functions in terms of e.g. complement 
activation in graft rejection (113). 
The role of IgG subclasses in graft rejection has not yet been fully investigated. 
Human IgG3 followed by IgG1 is the most potent complement binder of the 
subclasses. Human IgG4, the subclass present in the least concentration, is 
predominantly expressed in association with chronic antigen stimulation where it 
inhibits complement (C1q) binding.  
In their study Lee et al (114) used flow cytometry and obtained results that 
suggested that IgG1 and IgG2 were the dominant IgG subclass in ABOiRTx 
recipients. In ABOiRTx, the IgG isotype is clinically significant in predicting the 
outcome and risk of transplant rejection. Using a flow cytometric analysis, Stussi et 
al (98) reported that anti-ABO specific antibody subclass distribution of healthy 
individuals was composed mainly of IgG2 subclass. IgG1 and IgG3 subclasses 
constituted a small fraction and IgG4 was not detected.  
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The range of subclass detected in an earlier study by Kay(115) , using 
haemagglutination with subclass specific Antihuman globulin (AHG), demonstrated 
that subjects of all ABO groups had the capacity to produce IgG antibodies with 
each subclass, but those of group O produced the broadest spectrum of IgG 
subclasses and greatest strength of reactions. Another study suggested that IgG1 
and IgG2 were the dominant subclasses in ABOiRTx recipients and the baseline 
levels of these subclasses were found to correlate with the baseline total IgG titre 
(114). 
 
Immunoglobulin subclasses (IgG1, IgG2, IgG3 and IgG4) differ in their ability to 
activate the complement cascade and trigger rejection. The Fc portion of IgG1 and 
IgG 3 confer the ability to fix complement which then plays a role in graft rejection 
as described in Section 1.7(115). 
 
Among the IgG subclasses, IgG3 was found to recover relatively soon and 
seemed to be resistant to the effects of rituximab. The IgG3 level in the ABOiRTx 
patients recovered quickly from the effects of double filtration plasma pheresis, 
suggesting that IgG3 producing B-cells were resistant to rituximab (116). 
FcγR expression profiles of B-cells have been found to affect the dynamics of B-
cell subset depletion through targeting CD20. Fortunately, IgG3 is rarely induced 
in situations of ABO incompatibility and predominant subclass has been shown to 
be IgG2 rather than IgG3 (117) . 
 
The assessment of IgG subclass antibodies has not been extensively studied in 
ABOiRTx.  
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To risk-assess patients, their IgG subclass profile was investigated before 
desensitisation in order to describe the respective distribution of subclasses and 
correlate these with graft outcome. 
 
1.17 Scope of this thesis 
1.15 Scope of this thesis 
In order to make informed clinical decisions in the preparation and subsequent 
management of ABOiRTx patients, accurate and reproducible information of 
antibody levels and antibody activity is crucial. Therefore, the aim of this study is 
to: 
1. Compare commonly used ABO antibody titration methods and assess these for 
agreement/disagreement between them. 
2. Compare antibody titres obtained by each titration method against transplant 
outcome to determine association with graft survival. 
3. Develop an ELISA (Enzyme Linked Immunosorbent Assay) for reproducible 
measurement of anti-ABO IgG antibody subclasses. 
4. Determine association between anti-ABO IgG subclasses (as measured by the 
developed ELISA method) and ABOiRTx outcomes. 
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Chapter Two: Antibody Titration Methods 
This chapter presents the methods and outcomes for the Method Comparison study 
undertaken and subsequent evaluation of ABOiRTx patient samples. The first part of this 
study centres on the comparison of 6 ABO titration methods, which were then used to 
measure antibody titres in the samples from ABOiRTx patients.  
2.0 Study setting 
The study was carried out at Imperial College Healthcare NHS Trust (Hammersmith 
Hospital Blood Transfusion Department and Leslie Brent Laboratory). This is a teaching 
hospital and is one of the largest renal transplantation units in Europe, which made it ideal 
for this study.  
 
2.1 Study population and kidney donor demographics 
The whole study consisted of 50 samples taken from ESRD patients of which 30 had  
ABOiRTx. The other 20 samples were used to make up the optimal sample size as  
Calculated for the study but could not be used for calculations involving graft outcome data.  
as these patients had not yet had their transplants and therefore did not have graft outcome  
data. 
ABOiRTx transplant patients were recruited into the study by reviewing the Register for 
ABO-Incompatible Renal Transplant patients kept in the Blood Transfusion Laboratory at 
Hammersmith Hospital. The Register consisted of Special Forms showing the patient and 
donor blood groups and information on the recommended blood group of plasma required 
for Therapeutic Plasma Exchange. Only patients whose plasma samples were frozen from 
when they were transplanted and whose clinical history was easily accessible were selected 
into the study. A total of 30 patients were selected into the study, 12 females and 18 males. 
Mean age of participants was 50.42 years.  
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Average weight at transplantation was 76.9kg. 27% (n=8) of the study population were on 
both Rituximab and Daclizumab induction immunosuppressive treatment and 73% (n=22) 
on Rituximab only. 13% (n=4) of the recipients were onto their second kidney transplant and  
11 subjects had pre-emptive transplant performed while 19 were on dialysis while waiting 
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Figure 11 The primary causes of ESRD in study patients 
 
The mean age of the donors was 48.2 years and 59.4% of donors were male while 40.6% 
were female. The ethnic background distribution of donors that donated kidneys to study 
patients are shown in Fig 12. 
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Figure 12 Ethnic background distribution of donors that donated kidneys to study patients. 
  
The majority of the donor population consisted of white and Asian or Asian British 
individuals while Black or Black British and other ethnic minorities constituted the remainder 
of the donor complement and this population distribution is reflective of this part of London 
where a significant portion of the population are Asian or Asian-British and White.   
For the method comparison aspect of this study, plasma samples (n=50) obtained from both 
ABOiRTx pre-transplant ESRD patients routinely attending the Renal unit at the 
Hammersmith Hospital were used (Section 2.8). Of these 50, 30 had already had their 
ABOiRTx while 20 were ESRD patients awaiting transplantation as states in Section 2.1.   
 
2.3 Ethical consideration 
The study was approved by the Imperial College Healthcare NHS Trust Joint Research and 
Compliance Office at Hammersmith Hospital on the 8th of July 2013.  
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It was excluded from the ethical approval process as it was considered to be a Quality 
Assurance exercise as opposed to Research according to the HTA (Human Tissue 
Authority) definition. No new method was developed in this study but rather a comparison of 
well-established methodologies already available for operational use. In addition, no 
samples were collected prospectively but residual samples from the original method used at 
Imperial for ABO antibody titre measurement for clinical care during transplant were used. 
Plasma samples from all ABO incompatible transplant patients were frozen from 2005 to 
2015 and were available for analysis in this study. 
 
From the HTA (2004) (part 1 section point 10a)(118) and Royal College of Pathologists 
(RCPath) documents (Page 13 point 12)(119); it follows that as this is for Quality assurance 
purposes with no need for new specimens, no specific patient consent nor patient 
anonymity is required. 
Regarding patient sensitive information, the Renal team overseeing care of the patients 
reviewed the patients’ notes and relayed requested outcome data relevant to the study. 
 
2.4 Study design 
The cornerstone of many method evaluations is “Method Comparison” in which a set of 
specimens is assayed by both an existing method and the new method followed by 
comparison of results (120). Ideally in a method comparison study design, several methods 
are compared against a gold standard which if absent complicates this type of design. 
There is no gold standard method for ABO antibody titration therefore methods will have to 
be compared against each other for agreement. Four main points were considered in order 
to provide guidance in conducting the comparison of these methods(121): 
 Selection of the titration methods 
 Timing of the measurement 
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 Number of measurements  
 Conditions of measurement 
 
2.5 Selection of titration methods 
There are 2 main methodologies which are commonly used for ABO antibody titration i.e. 
conventional tube and column methods. Due to the use of different variations of these 
methods, all available methods were gathered, and the most common ones were selected 
and assessed for agreement. All institutions performing ABOiRTx in the UK and a few 
representative external laboratories were contacted to obtain their antibody titration 
protocols.  
 
Most titration methods were obtained from the UK National External Quality Assurance 
Scheme (NEQAS) who had record of individual hospital titration methodologies. The 
methods were then entered into a spreadsheet and checks were carried out for procedural 
similarities and differences after which methods with the greatest differences were selected 
into the study to ensure a fair representation of each method variation. A total of 6 methods 
were selected into the study. 
 
2.6 Timing of measurements 
As the main objective of this part of the study was to determine if the titration methods 
under investigation could be used interchangeably to measure antibody levels, the testing 
should ideally have been carried out at the same time to guarantee consistency of assay 
conditions. 
However, this was not possible as one individual conducted all tests in the study to exclude 
inter-observer variation. 
 
                                                                   Antibody Titration Methods 
Page 59 of 138 
 
Multiple small batches (e.g. 5 samples) were run tested at the same time over a month to 
accommodate between-day variations. To monitor “between/inter day variations”, a 
previously tested sample was run in parallel with a current batch of samples to ensure 
repeatability by checking if the same result was produced. 
 
2.7 Number of measurements 
For the Method Comparison study, an initial pilot study was conducted on 10 renal patient 
samples in order to generate preliminary data so the number of samples required for the full 
method comparison study (referred to as the main study) could be determined. Paired 
titrations were performed on each sample to reduce chance findings and also to facilitate 
application of the statistical method chosen for data analysis.  
Large numbers of sets of paired measurements add precision to the results and cause the 
data to approach a normal distribution thus enabling the use of bias and precision statistics. 
Duplicate titrations were performed on both the pilot and main study samples on each 
sample to allow for agreement statistics to be applied. These 2 sets of data were analysed 
and presented both separately and combined.  
 
2.8 Sample inclusion criteria 
Samples used for the method comparison study were from ESRD patients pre-transplant. 
All samples met the minimum acceptable demographics for Blood Transfusion i.e. First 
name, surname, Hospital number, date of birth and gender.  
Samples were also checked for adequacy to ensure enough volume for all measurements 
to cover all 6 methods compared. Only samples with readily accessible clinical outcome 
data were selected into the study. 
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Samples with other red cell antibodies apart from the naturally occurring ABO antibodies 
were titrated against reagent cells that did not have the corresponding antigen to avoid false 
elevation of the titre. 3 samples were processed in this manner. 
 
2.10 Comparison of haemagglutination antibody titration methodologies 
2.10.1 Preparation of serial dilutions 
For each plasma sample tested, dilutions (Master dilution (Neat), 1/2, 1/4, 1/8, 1/16, 1/32, 
1/64, 1/128, 1/256, 1/512, 1/2048) were carried out in Phosphate Buffered Saline (P.B.S.S) 
(Inverclyde Biologicals®, United Kingdom). To achieve this serial dilution, 1 volume of 
P.B.S.S was added to each of the dilution tubes labelled 1/ 2 up to 1/2048.1 volume of neat 
plasma was added to 1 volume of P.B.S.S in the tube marked 1/ 2 and mixed. 1 volume of 
this dilution was then transferred to the next tube marked 1/ 4 and the process repeated 
until the last tube marked 1/2048. 
With each transference of plasma, a new pipette tip was used to avoid cross-contamination 
between individual dilutions due to carryover which may systematically cause a falsely 
elevated antibody titre. An automated calibrated pipette was used to ensure consistency in 
volumes through elimination of pipetting technique as a variable. 
 
2.10.2 Dithiothreitol (DTT) for the inactivation of IgM antibodies 
DTT (Dithiothreitol) predominantly degrades IgM by reduction of intermolecular disulphide 
bonds, and is therefore useful to determine the presence of IgG antibodies in the 
haemagglutination assay (98).  
Plasma samples are first treated with 0.1 M DTT reagent (NHSBT) in a 1:1 ratio then 
incubated for 30 min at 37◦C, and this allows for measurement of only IgG class antibodies 
after destruction of IgM by the DTT. Titration is then performed as described above in 
section 2.10.1. DTT is preferred as it is more resistant to oxidation in air and more efficient 
as a reducing agent than 2-Mercaptoethanol (2-ME).  
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DTT acts by cleaving the disulphide bonds of pentameric IgM thus abolishing agglutinating 
and complement binding activities. This allows the detection of IgG antibodies in plasma. 
The negative control for the titration of anti-A and anti-B, IgM and IgG methods was the 
serial dilution of serum against blood group O cells, since blood group O has neither A nor 
B antigens and therefore no agglutination is expected. 
 
2.10.3 Conventional tube Haemagglutination assay for the quantitation of IgM/IgG 
antibodies 
One volume of 3% A1, B or O blood group cells (National Health Service Blood and 
Transplant (NHSBT) reagents United Kingdom) was then added to each serial dilution of 
plasma.  
All tubes were incubated (37◦C, 45 mins) then centrifuged at 1000 x g for 30s.  
All dilutions were then washed with P.B.S.S using an automated cell washer (Medion 150) 
and after the 4th wash, polyspecific anti-human-globulin (AHG) (Biotest ®, Germany) was 
added to each sample and centrifuged for a further 30s at 1000 x g. Each tube was then 
examined macroscopically for agglutination using the grading shown in Fig13. The inverse 
of the highest dilution producing agglutination was recorded as the IgM or IgG titre for that 
sample. 
 
Red cells were obtained from NHSBT supplies (NHSBT Liverpool) for column method; A1rr 
(product code PR014); Brr (Product code PR035) in CellStab suspension, 0.8 ± 0.2% 
concentration/ML. 3% red cell suspension in Alsevers was also obtained from NHSBT 
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All samples with a recent transfusion history were screened for antibodies using 3 set of 
screening cells with a homozygous expression of the most commonly encountered 
alloantibodies whose presence in the patient’s plasma may falsely elevate antibody titre due 
to their IgG nature. 
 
DTT treatment was also used in this study in order to objectively measure the titre of IgG 
anti-ABO antibodies (as stated above in Section 2.10.2) 
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4+ agglutination: Red cell button is a 




3+ agglutination: Red cell button 






2+ agglutination: Red blood cell button 
breaks into many medium-sized 
agglutinations: Clear background; No 




1+ agglutination: Red cell button 
breaks into many small clumps barely 
visible ground macroscopically: 






Negative: No agglutinated red cells 
present. Red cells are observed 
flowing off the red cell button. 
 
2.10.3 Column agglutination  
2.10.3.1 Bio-Rad technique 
Bio-Rad IAT cards were used for the IAT titration of IgG anti-ABO antibodies while Bio-Rad 
NaCl cards were used for the room temperature direct agglutination technique for 
determination of IgM anti-ABO antibodies. 
Figure 13 Grading of Tube Haemagglutination reactions 
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 The Bio-Rad IAT cards were labelled with each patient’s unique identifier, where 
appropriate and 50µl of the required ABO group Diluent 2- or Cellstab-suspended red cells 
were dispensed into appropriately labelled wells of the Bio-Rad IAT or NaCl cards. 25µl of 
each plasma dilution was added to the appropriate well of the IAT or NaCl card. The NaCl 
cards were incubated at room temperature for 15 minutes (Room temperature maintained 
between 20◦C and 24◦C and controlled by AAW control systems). The IAT cards were 
incubated at 37◦C for 15 minutes. Following incubation, the cards were centrifuged in a 
Diamed centrifuge for 30s at 85 x g. The cards were then manually read on a light box, the 
results were graded, and the titre recorded. 
 
In cases where the end point was not reached, the titration was extended by performing 
further dilutions until a negative result was obtained. 
 
Reagent red blood cells were obtained from NHSBT Liverpool: Arr, Brr and OR1r, in Cell 
stab 0.8±0.2% concentration/ml. 
 
For the DTT technique, 300 µl of plasma was diluted with 300µl of 0.1M DTT reagent 
(NHSBT) and incubated for 30 minutes at 37◦C. PBS was then used for serial dilutions of 
plasma using the doubling dilution method (Section 2.10.1). The Indirect agglutination using 
antiglobulin technique (IAT) used 50µl of red cells suspended in ID Diluent 2 to each 
microtube and then 25µl of the DTT treated plasma serially diluted from 1:1 with ID Diluent 
2.  
Gel cards containing anti-IgG in the columns were used (004025, Coombs Anti-IgG, Bio-
Rad, UK). This was incubated at 37◦C for 15 minutes and then centrifuged at 85 x g and 
read as per the previous procedure. 
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Direct agglutination at room temperature (DRT) was performed using neutral Bio-Rad cards 
(005015, NaCl, Enzyme Test and cold Agglutinins, Bio-Rad, UK) with 50µl of RBCs 
suspended in ID Diluent 2 to each microtube. 50µl of each plasma dilution was added to the 
corresponding microtube and incubated at room temperature for 15 minutes. The gel cards 
were centrifuged (85 x g) for 10 minutes in DiaMed (1-Centrifuge 12S-II, Bio-Rad, UK). The 
gel cards were analysed over a light box and the last well giving a positive result of 
agglutination was recorded as the titre result for that sample (Fig14).  
 
A single user performed all haemagglutination assays for historic control samples in parallel 
with study samples during each run to check for reproducibility of technique. 
 
Figure 14 An example of reactions in a typical gel or glass bead column card 
 
2.10.3.2 BioVue technique 
Using the OrthoBioVue glass bead column technique, 50µl 0.8% test red cell suspension 
was added to 40µl of plasma (with or without DTT treatment) in a glass bead cassette 
(BioVue® -Anti-Human Globulin anti-IgG) and incubated 15 minutes.  
The cassettes were spun using OrthoBioVue centrifuge using a two-stage centrifugation 
first at 793rpm for 2min followed by 1509rpm for 3min in one cycle.  
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The cards were then manually read on a light box, the results were graded, and the titre 
recorded as shown in Fig 14. 
 
2.11 Data Analysis 
For the method comparison aspect of the study, because 6 methods were being compared 
for agreement without a reference standard, methods like Correlation or Bland-Altman plot 
were not suitable as they are suitable mainly for 2 method comparison designs. Repeated 
Measures ANOVA (using IBM SPSS 25) was therefore used to determine agreement 
between the antibody titration methods and the following assumptions were made: 
 Independent and identically distributed variables observations 
 Test variables follow a multivariate normal distribution in the population (Assumption 
not necessary if sample size ≥ 25) 
 Sphericity-The population variances of all possible difference scores are equal. This 
was tested with Mauchly’s test. 
 
The ABO antibody titration results obtained following analysis of the ABOiRTx patient 
samples using the methodologies used in this study were also compared with the 
associated results that were obtained by the reference laboratory at the time of 
transplantation. This was done in order to determine whether different clinical decisions 
would have been made if any of the methodologies considered in this study were used.  
 
One assumption for this model is that the measured quantity i.e. “antibody titre per sample” 
remains unchanged across the measurements made by the same method(122). Therefore, 
throughout the study, sample integrity was maintained as samples were kept frozen in 
aliquots and only thawed when required. 
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Further: 
 If acceptable agreement between methods was noted, then any of the titration methods 
could be used interchangeably. 
 If disagreement between methods was noted, then a proxy reference standard would be 
used to determine the method that best predicts the clinical outcome i.e. transplant 
survival. 
 
Transplant outcome data was retrieved from patients’ historical records and the diagnosis 
was made through routine biopsies of the renal allografts performed at transplantation and 
before the first discharge, and episode biopsies were performed in case of graft dysfunction. 
The biopsy samples were examined using light microscopy and also using 
immunofluorescent staining in order to check for deposit of C4d in the peritubular capillaries 
and graft rejection was histologically diagnosed using these graft biopsy specimens using 
the Banff 2007-2013 criteria (Outcome diagnosis was made prior to this study). Survival 
analysis was carried out using the Kaplan-Meier over a period of 3 years. 
 
2.11.1 Unique problem with handling titration data 
Titres are discrete values following a geometric progression due to serial dilution i.e. the 
results can only take any value as follows: 2, 4, 8, 16 …. (2)n. Therefore, the difference 
between 2 readings e.g. 2 & 4 and 4 & 8 is not the same because the progression follows 
an exponential function. 
 
 
In terms of dilution the difference between titres is uniform (i.e. 1 dilution between each titre) 
but for calculation purposes the exponential nature of the titration values distorts the reality 
and creates a problem when analysing data.  
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Therefore, to obtain linearity, all titration data was converted to logarithms to base 2 to 
enable easy analysis. Thus, in all calculations involving titres in this study, titre values were 
presented as Log (base 2) where a titre of 2 represented Log22 =1, titre of 4 represented 
Log24= 2 etc. as shown in Table 3. 
 





2.12. Pilot Study Results 
The 6 methods used in the pilot (and then main) study are shown in Table 4 below. Each 
titration was tested in duplicate using each method for each of the samples and the 
duplicate results were designated A1 and A2; B1 and B2 etc. However, for subsequent 
statistical analysis, the duplicate measures were averaged out to allow for comparisons 
across the different methodologies once good reproducibility was demonstrated.  
 
 







results by each method) 
Tube IAT A1, A2 
Tube DRT B1, B2 
Bio-Rad IAT C1, C2 
Bio-Rad DRT D1, D2 
BioVue IAT E1, E2 
BioVue DRT F1, F2 
Titre 0 2 4 8 16 32 64 
Log (base 2) 0 1 2 3 4 5 6 
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As stated previously, a pilot study using 10 samples (these were also included in the 50 
samples used in the study)  from routine ESRD patients on haemodialysis was conducted 
initially in order to ensure protocol and device familiarisation, to determine reproducibility 
and also to obtain data for a sample size calculation for the main method comparison study. 
The pilot study was also used to determine repeatability and hence reliability of each 
titration method. 
Table 5 and Fig 15 shows the results (in duplicates) obtained for all pilot samples which 
were randomly chosen from ESRD patients on dialysis.  
 























1 32    32 64   128 256    256 256   256 512    512 256   256 
2 64   128 128   128 256    512 512   512 512   1024 512   512 
3 32    16 32      32 32     64 64       64     128    128 128   128 
4 256   512 256     256 256    512 512   512 512    512 512   512 
5 128   128 256    128 512     512 1024   1024 1024   1024 2048   2048 
6 512   512 256     256 512   512 512    512 1024   2048 2048 2048 
7 32    64 32    64 64      64 64         64 64   64 64   64 
8 256   256 256   512 512   512 512     1024 512   1024 1024   1024 
9 32   16 16    16 16   32 128    128 128   128 128 128 
10 64   32 64     64 32     64 64       64 128    256 128 128 
 
2.12.1 Using pilot study data to calculate sample size 
Based on a sample of 10 subjects, pairwise coefficients of individual agreement were 
calculated. The standard errors (SEs) of the coefficients ranged from 0.03 to 0.22. To make 
the sample size calculation conservative, the largest standard error of 0.22 was used.  
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The aim was to use a sample size large enough so that the width of the 95% confidence 
interval (CI) would not exceed 0.4. Therefore, the CI will be (0.40,0.80). Since the width of 
the CI is approximately 4 times the SE, the required SE was set to 0.1.  
 
As SE is known to be inversely proportional to the square root of the sample size, therefore 
in order to decrease the SE from 0.22 to 0.1, the sample size will have to be increased by a 
factor of (0.22/0.1)2   i.e. by 4.84. Since the sample size used in this pilot was 10, at least 
49 subjects will be needed to achieve the CI goal. The sample size for titration method 
comparison in this study was set at 50. 
 
2.12.2   Comparison of titre distributions for pilot samples as measured by different 
titration methodologies.  
Figure 15  shows box and whisker plots of duplicate titre readings measured by the 6 
methods chosen in the study as displayed in Table 5.  
Method designations i.e. Method A1 and Method A2 denote duplicate titres on study 
samples as measured by each method (For method descriptions, see Table 4) 
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Figure 15 Box and Whisker plots showing duplicate titre readings as measured by the 6 methods in the pilot study 
 
Overall, methods D (Bio-Rad DRT) and F (BioVue DRT) gave higher mean titres (titres 
expressed to log2) compared to the others. Methods A (Tube IAT), B (Tube DRT) and C 
(Bio-Rad IAT) gave the highest range while methods A and B gave the lowest mean titres. 
These results demonstrate a wide variation of distributions of results obtained by each 
method on the same samples. Methods D and F tend to give higher titres than the rest of 
the methods. In general, this means that choosing to use method D and F over A, B or C 
may result in overpreparation or underpreparation of patients for ABOiRTx unless one out of 
the 2 groups of methods is proven to be associated with graft survival compared to the 
other. 
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Since the titrations were carried out on different days using the different methodologies, 
inter-day and intra-test reproducibility needed to be established. 
 
2.12.3 Intra-test and inter-day reproducibility of haemagglutination assay for IgG and 
IgM ABO antibodies on pilot samples 
The Cronbach’s coefficient was used to determine the level of reproducibility as shown in 
Table 6. 
























Tube IAT 0.94 0.95 12.8 3.16 10 
Tube DRT 0.95 0.94 13.2 2.79 10 
Bio-Rad IAT 0.98 0.97 14.7 3.35 10 
Bio-Rad DRT 0.99 0.97 15.9 2.98 10 
BioVue IAT 0.97 0.99 17 2.86 10 
BioVue DRT 1.0 0.98 17 3.38 10 
 
The intra-test and inter-day repeatability showed good ‘test-retest’ reliability for all 6 
methods as measured by the Cronbach’s Alpha reliability coefficient (α) which calculates 
the inter- and intra-test Correlation coefficient. Effectively, Cronbach's alpha measures 
internal consistency of a method or how closely related the antibody titres are as a group. 
As the average inter-method correlation increases, Cronbach's alpha also increases. One of 
the underlying assumptions for the Cronbach’s alpha is that all of the titre measurements 
were entirely independent from one another. Cronbach’s alpha for both inter-day and intra-
test was >0.90 thus demonstrating good reproducibility. 
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This level of consistency as demonstrated in the pilot study provided the confidence needed 
to proceed with the testing of the rest of the study samples. This high level of reproducibility 
also justified the use of average titres of each of the pairs of measurements performed on 
each sample by each individual method. Titration reproducibility was monitored throughout 
the study especially as different batches of pooled red blood cells were obtained from 
NHSBT reagents laboratory in Liverpool to ensure consistency of results. 
 
2.12.4 Statistical analysis for pilot study Direct Room Temperature Agglutination 
(DRT) titration methods 
For statistical analysis, methods that used the Direct Room Temperature agglutination 
(DRT) methodology were analysed separately from those that used Indirect Agglutination 
(IAT). The BioVue DRT method had the highest mean titre compared to Tube and Bio-Rad 
DRT methods as shown in Table 7. This might be an early indication of the possibility of 
overestimation by the BioVue DRT method. 
 
Table 7 Estimated Marginal Means and Standard Error of Titres against their respective Methodologies used. 
Estimated Marginal Means 
Measure: Antibody titre 









Tube DRT 6.600 0.464 5.550 7.650 
Bio-Rad DRT 7.950 0.497 6.826 9.074 
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In order to assess for overall comparability across these methods, ANOVA with repeated 
measures was used as shown in Table 8. 
 
Table 8 ANOVA between all Antibody DRT antibody Titration Methodologies in the pilot 
 
The results show that there was overall significant difference between the ABO antibody 
titre means as measured by the different titration methods. From these results, the mean 
scores for the antibody titres were statistically different: F (2, 18) =24.995, p=0.000. 
 
The results demonstrate that there is an overall significant difference in the means obtained 
by the 3 titration methods. As a result of this statistically significant difference, pairwise 
comparisons were carried out in order to determine which specific means differed.  
 
Significance testing was done using the Bonferroni post hoc test (adjustment for multiple 
comparisons) and this is shown in Table 9 which shows the significance level for differences 
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Table 9 Pairwise comparison of ABO antibody titres against the DRT Antibody Titration methodology in the pilot 
Pairwise Comparisons 
Measure: ABO Antibody Titre 
(I) Antibody Titration Method 
Mean 
Difference 
(I-J) Std. Error Sig.b 






Tube DRT Bio-Rad 
DRT 
-1.350* 0.289 0.004 -2.198 -0.502 
BioVue 
DRT 
-1.900* 0.314 0.001 -2.822 -0.978 
Bio-Rad DRT Tube DRT 1.350* 0.289 0.004 0.502 2.198 
BioVue 
DRT 
-0.550 0.217 0.095 -1.186 0.086 
BioVue DRT Tube DRT 1.900* 0.314 0.001 0.978 2.822 
Bio-Rad 
DRT 
0.550 0.217 0.095 -0.086 1.186 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
There was a significant difference in antibody titre between Tube DRT and Bio-Rad DRT 
(p=0.004) and between Tube DRT and BioVue DRT (p=0.001). However, there was no 
significant difference between Bio-Rad DRT and BioVue DRT (p=0.095). 
 
2.13.3 Statistical analysis for pilot study IAT Titration Methods 
Statistical analysis was carried for the IAT methods in a similar way as for the DRT methods 
in Section 2.12 above. Table 10 shows the means and standard errors pilot sample of titres 
against the IAT methods.  
Table 10 Estimated Marginal Means and Standard Error of titres against their respective methodologies 
 
 
BioVue IAT method had the highest mean titre and range compared to Tube IAT and Bio-





Tube IAT 6.600 0.482 5.510 7.690
BioRad IAT 7.350 0.558 6.088 8.612




Measure: ABO antibody titre
AntibodyTitrationMethod Mean
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This pattern was also observed above with the DRT methods which seems to suggest that 
higher titration values are likely to be associated with both the IAT and DRT BioVue 
methods.  
 
Overall significance testing was performed for IAT methods using ANOVA with repeated 
measures and the results are shown in Table 11. 
 
Table 11 ANOVA between all IAT antibody titration methodologies in the pilot 
Tests of Within-Subjects Effects 











19.350 2 9.675 16.100 0.000 
Greenhouse-
Geisser 
19.350 1.467 13.189 16.100 0.001 
Huynh-Feldt 19.350 1.682 11.504 16.100 0.000 






10.817 18 0.601     
Greenhouse-
Geisser 
10.817 13.204 0.819     
Huynh-Feldt 10.817 15.139 0.715     
Lower-bound 10.817 9.000 1.202     
 
There was a statistically significant difference (p<0.005) between the IAT methods in this 
pilot study therefore pairwise comparisons were performed to identify where the specific 
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Table 12 Pairwise comparisons of IgG titres against antibody titration methodology 
Pairwise Comparisons 
Measure: Antibody titre 
(I) Antibody Titration Method 
Mean 
Difference 
(I-J) Std. Error Sig.b 
95% Confidence 





Tube IAT Bio-Rad IAT -0.750 0.417 0.316 -1.972 0.472 
BioVue IAT -1.950* 0.369 0.001 -3.031 -0.869 
Bio-Rad 
IAT 
Tube IAT 0.750 0.417 0.316 -0.472 1.972 
BioVue IAT -1.200* 0.226 0.001 -1.863 -0.537 
BioVue 
IAT 
Tube IAT 1.950* 0.369 0.001 0.869 3.031 
Bio-Rad IAT 1.200* 0.226 0.001 0.537 1.863 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 









Pairwise investigations showed that the only agreement was found between Tube IAT and 




df Error df Sig.
Pillai's 
trace
0.852 23.114a 2.000 8.000 0.000
Wilks' 
lambda
0.148 23.114a 2.000 8.000 0.000
Hotelling's 
trace




5.779 23.114a 2.000 8.000 0.000
Multivariate Tests
Each F tests the multivariate effect of AntibodyTitrationMethod. These 
tests are based on the linearly independent pairwise comparisons a. Exact statistic
Table 13 Multivariate analysis showing overall significance between all IAT 
antibody titration methodologies in the pilot study 
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2.13.4 Statistical analysis for pilot study IAT and DRT Titration Methods 
Multivariate analysis of both IAT and DRT methods was carried out to determine 
significance. The results are shown in Table 14. 
Table 14 Multivariate analysis showing overall significance of both IgG and IgM titres against all methodologies 
 
 
The investigation shows that there was a statistically significant difference between both IAT 
and DRT methods F (6.983), p=0.026. Since this was a pilot study, pairwise comparisons 
were performed to obtain a clearer picture of what to expect in the larger sample size i.e. n= 
50 in the substantive study as calculated in Section 2.12.1.  
 
















0.875 6.983a 5.000 5.000 0.026 0.875
Wilks' 
lambda
0.125 6.983a 5.000 5.000 0.026 0.875
Hotelling's 
trace




6.983 6.983a 5.000 5.000 0.026 0.875
Multivariate Tests
Each F tests the multivariate effect of AntibodyTitrationMethod. These tests are 
based on the linearly independent pairwise comparisons among the estimated a. Exact statistic
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Table 15 Pairwise comparisons of titres against DRT and IAT Antibody titration methodologies on pilot samples  
Pairwise Comparisons 
Measure: ABO Antibody titre 
(I) Antibody Titration Method Mean 
Difference 
(I-J) 
Std. Error Sig.b 
95% Confidence 





Tube IAT Tube DRT -0.750 0.417 1.000 -2.398 0.898 
Bio-Rad IAT -1.950* 0.369 0.007 -3.407 -0.493 
Bio-Rad DRT 0.000 0.279 1.000 -1.103 1.103 
BioVue IAT -1.350 0.388 0.104 -2.883 0.183 
BioVue DRT -1.900* 0.371 0.009 -3.368 -0.432 
Tube DRT Tube IAT 0.750 0.417 1.000 -0.898 2.398 
Bio-Rad IAT -1.200* 0.226 0.007 -2.094 -0.306 
Bio-Rad DRT 0.750 0.201 0.070 -0.044 1.544 
BioVue IAT -0.600 0.233 0.452 -1.523 0.323 
BioVue DRT -1.150* 0.279 0.039 -2.255 -0.045 
Bio-Rad IAT Tube IAT 1.950* 0.369 0.007 0.493 3.407 
Tube DRT 1.200* 0.226 0.007 0.306 2.094 
Bio-Rad DRT 1.950* 0.252 0.000 0.953 2.947 
BioVue IAT 0.600 0.194 0.195 -0.169 1.369 
BioVue DRT 0.050 0.174 1.000 -0.638 0.738 
Bio-Rad 
DRT 
Tube IAT 0.000 0.279 1.000 -1.103 1.103 
Tube DRT -0.750 0.201 0.070 -1.544 0.044 
Bio-Rad IAT -1.950* 0.252 0.000 -2.947 -0.953 
BioVue IAT -1.350* 0.289 0.018 -2.493 -0.207 
BioVue DRT -1.900* 0.314 0.003 -3.143 -0.657 
BioVue IAT Tube IAT 1.350 0.388 0.104 -0.183 2.883 
Tube DRT 0.600 0.233 0.452 -0.323 1.523 
Bio-Rad IAT -0.600 0.194 0.195 -1.369 0.169 
Bio-Rad DRT 1.350* 0.289 0.018 0.207 2.493 
BioVue DRT -0.550 0.217 0.477 -1.407 0.307 
BioVue DRT Tube IAT 1.900* 0.371 0.009 0.432 3.368 
Tube DRT 1.150* 0.279 0.039 0.045 2.255 
Bio-Rad IAT -0.050 0.174 1.000 -0.738 0.638 
Bio-Rad DRT 1.900* 0.314 0.003 0.657 3.143 
BioVue IAT 0.550 0.217 0.477 -0.307 1.407 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
Out of all the pairwise comparisons, the following pairs of methods: Tube IAT/Tube DRT, 
Tube IAT/Bio-Rad DRT, Tube IAT/BioVue IAT, Tube DRT/BioVue IAT, Bio-Rad IAT/BioVue 
IAT, Bio-Rad IAT/BioVue DRT, BioVue DRT/BioVue IAT showed no statistically significant 
difference (p>0.05) hence demonstrated agreement. 
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Following the completion of the pilot study, 40 more samples (30 from ABOiRTx patients 
and 10 from ESRD patients awaiting transplantation) were processed in a similar manner as 
the calculated sample size for 80% statistical power was n=50 (Section 2.12.1). The results 
are shown in the next section. 
 
2.14 Analysis of all study samples against all titration methods 
Following the same format as used for the pilot study in Section 2.13 above, the same 
analyses were carried out on the full complement of study samples (n=50) which also 
included the pilot samples (n=10). Table 16 shows ANOVA results between DRT methods 
on all study samples.  
Table 16 ANOVA between DRT titres against Titration methodology 
 
 
Sphericity assumption for ANOVA was not met hence the Greenhouse-Geisser correction 
was used. Repeated measures ANOVA determined that the mean antibody titres differed 












161.090 5 32.218 51.425 0.000 0.512
Greenhouse-
Geisser
161.090 2.877 55.997 51.425 0.000 0.512
Huynh-Feldt 161.090 3.075 52.384 51.425 0.000 0.512







Huynh-Feldt 153.493 150.684 1.019
Lower-bound 153.493 49.000 3.133
Tests of Within-Subjects Effects
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Table 17 Pairwise comparisons between antibody titres and Titration methodologies on all study samples 
 
 
The results of pairwise comparisons in Table 17 show that the only methods that 
demonstrated agreement were Tube IAT and Tube IgM, Tube IgM and Bio-Rad IAT, Bio-
Rad IgM and Bio-Vue IAT i.e. (p=1.00) (CI: -0.12, 0.461), p=0.054 (CI -0.703-0.003) and 





Tube IgM -0.170 0.094 1.000 -0.461 0.121
BioRad IAT -.520* 0.149 0.016 -0.980 -0.060
BioRadIgM -1.140* 0.196 0.000 -1.746 -0.534
BioVue IAT -1.550* 0.205 0.000 -2.183 -0.917
BioVueIgM -2.020* 0.176 0.000 -2.563 -1.477
Tube IAT 0.170 0.094 1.000 -0.121 0.461
BioRad IAT -0.350 0.115 0.054 -0.703 0.003
BioRad IgM -.970* 0.178 0.000 -1.518 -0.422
BioVue IAT -1.380* 0.188 0.000 -1.961 -0.799
BioVue IgM -1.850* 0.166 0.000 -2.363 -1.337
Tube IAT .520* 0.149 0.016 0.060 0.980
Tube IgM 0.350 0.115 0.054 -0.003 0.703
BioRad IAT -.620* 0.174 0.013 -1.157 -0.083
BioRad IgM -1.030* 0.128 0.000 -1.425 -0.635
BioVue IgM -1.500* 0.153 0.000 -1.973 -1.027
Tube IAT 1.140* 0.196 0.000 0.534 1.746
Tube IgM .970* 0.178 0.000 0.422 1.518
BioRad IAT .620* 0.174 0.013 0.083 1.157
BioVue IAT -0.410 0.154 0.159 -0.886 0.066
BioVue IgM -.880* 0.124 0.000 -1.263 -0.497
Tube IAT 1.550* 0.205 0.000 0.917 2.183
Tube IgM 1.380* 0.188 0.000 0.799 1.961
BioRad IAT 1.030* 0.128 0.000 0.635 1.425
BioRad IgM 0.410 0.154 0.159 -0.066 0.886
BioVue IgM -.470* 0.126 0.008 -0.860 -0.080
Tube IAT 2.020* 0.176 0.000 1.477 2.563
Tube IgM 1.850* 0.166 0.000 1.337 2.363
BioRad IAT 1.500* 0.153 0.000 1.027 1.973
Biorad IgM .880* 0.124 0.000 0.497 1.263
BioVue IAT .470* 0.126 0.008 0.080 0.860
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
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2.15 Risk factors affecting transplant outcome 
Several factors may affect graft outcome and thus acting as confounders when assessing 
the effect of antibody titres on ABOiRTx outcome. These factors include HLA 
incompatibility, comorbidities like diabetes mellitus, age at transplant and whether the 
transplant was pre-emptive or followed a period of dialysis and are listed below.  
 Number of previous transplants 
 Immunosuppressive drugs 
 Age/Gender of donor or recipient 
 Weight 
 Dialysis vs pre-emptive transplantation  
 HLA antibody sensitisation 
Table 17 below summarises the most common risk factors associated with ABOiRTx 
outcome as identified by the British Transplantation Society in the Guidelines for Antibody 
incompatible transplantation (123).  
Table 17 Main risks associated with ABOiRTx 
Factor High risk Low risk 
Haemagglutination titre >1/256 Any level 
If donor is group A Group A1 Group A2 
Donor type Deceased donor Living Donor 
HLA antibody incompatibility Yes No 
(Adapted from British Transplant Society Guidelines 2015)(107) 
 
Unfortunately, these potential confounders could not effectively be factored into graft 
outcome statistical inferences as the information was not consistently recorded.  
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Therefore, the only risk factor which could be investigated was ‘baseline ABO antibody 
levels’ against transplant outcome.  
2.15 Comparison of titration methodologies used in the study against 
methodologies used by other centres in the NEQAS program 
In order to determine comparability of the study results against other centres, the study was 
registered to participate in a NEQAS ABO antibody titration pilot exercise from 2012 to 2015 
and a total of 12 exercises were performed. A maximum of 441 submissions from all 
participants were sent in this exercise, most of them from the United Kingdom and some 
from other parts of the world.  
 
In the current study only the proposed standard DRT and IAT methods were registered and 
submitted to the NEQAS survey with and also without DTT treatment. The survey looked at 
14 different titration methods. Figure 16 summarises the methodologies used and the 
respective submissions made under each category. Reproducibility was also assessed in 
one of the survey exercise distributions through blind-testing of 2 identical samples 
containing anti-A antibody i.e. Sample 2 and sample 3 as shown in the Table 18. 
 
Table 18 Intra-laboratory reproducibility of testing 2 identical samples against different methodologies 
 




DRT Standard (48) 43 (90%) 5 (10%) 0 (0%)
IAT Standard (54) 41 (76%) 13 (24%) 0 (0%)
DRT In-house  (46) 38 (83%) 8 (17%) 0 (0%)
IAT In-house 
untreated (29)
16 (55%) 12 (41%) 1 (4%)
IAT In-house DTT 
treated (8)
4 (50%) 4 (50%) 0 (0%)
Technique (Number 
of results)
Results Patient 2 vs. Patient 3
Number (%) 
Identical
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‘DRT standard’ and ‘DRT In-house’ techniques showed good reproducibility i.e. both 
showing the highest number of identical results (90% and 83% respectively) and 0% of 
results showed a difference of greater than 1 dilution on the identical samples tested. The 
proposed IAT Standard technique also showed good reproducibility with 0% of the results 
>1 dilution apart and 76% of identical titres obtained. The IAT in-house untreated technique 
was the only one that had 4% of results showing >1 dilution difference with 41% of the 
results 1 dilution apart. The IAT in house DTT treated technique was the least used 
technique with equal proportions (50%) of titres identical and also within 1 dilution 
difference, however, the proportion may have been affected by the small number of 
samples tested using this methodology. 
 
Figure 16 shows the number of submitted results against respective methodologies as 
submitted to NEQAS. This shows that DRT and IAT standard methods were the most 









Figure 16 Number of submitted results against titration methodology in a UK NEQAS exercise 
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Immucor and Tube methodologies were the least used methodologies in the survey while 
DTT treatment was only used by a small number of centres. 
Overall, the results obtained through participation of our study in this scheme were either 
identical to or within 1 dilution of the method median. This overall comparability 
demonstrated that the methodologies used in this study produced results that were in 
consensus with the majority of centres using similar or different methodologies. 
 
The titrations in this study were run by one individual to mitigate the effect of inter-operator 
variability thus maintaining a level of objectivity throughout the study. 
 
2.11.5 Transplant survival against antibody titration results for the ABOiRTx patients  
A Kaplan Meier method was used for survival analysis for determining if there was any 
difference in survival between ABOiRTx patients with low and those with high baseline ABO 
antibody titres.  
High or Low titre levels were defined as ≤64 and >64 respectively. The titre levels were 
determined for each patient based on this criterion as measured by each of the methods 
considered in this study. For graft outcome, records were retrospectively reviewed over a 5-
year period and any cases that went over this period were “censored” (i.e. patients that did 
not experience graft rejection or died with a functioning graft in the defined period). 
 
Table 19 below shows that a high percentage 66.7 % (n=14) of cases were censored in the 
low ABO antibody group compared to the high antibody group i.e. 33.3% (n=3). The event 
in this study was defined as “Graft rejection”. "High” antibody titre was defined as >64 while 
“Low” titre was defined as ≤64. From Table 19, it appears that high antibody level is 
associated with poor graft survival. 
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Table 19 Antibody titre against censored cases over a 5- year period 
Case Processing Summary 





High 9 6 3 33.3% 
Low 21 7 14 66.7% 
Overall 30 13 17 56.7% 
 
Table 20 demonstrates that poor prognosis is associated with high ABO antibody group i.e. 
mean survival time for the Low antibody group was higher at 3.789 (SE 0.473) years 
(CI=0.466-3.872) compared to the High antibody group which was 2.169 years (SE=0.869) 
(CI=0.466-3.872). 
 
Table 20 Measures of Central tendency for Survival time between High and Low antibody levels 
 
 
Overall, there was no statistically significant difference in graft survival (p>0.05) between 
the High and Low ABO antibody titre groups over a 5-year period as shown in Table 21 as 









High 2.169 0.869 0.466 3.872 1.100 0.481 0.156 2.044
Low 3.789 0.473 2.862 4.717
Overall 3.313 0.431 2.469 4.157 5.000
95% Confidence 
Interval
a. Estimation is limited to the largest survival time if it is censored.
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            Table 21 Overall comparison of graft survival between high and low ABO antibody titre groups 
 
The Kaplan–Meier survival curves for the 2 ABO antibody groups (High and Low) as 
measured by the Reference Laboratory IAT method, Fig17, show different survival patterns 




Figure 17 ABO IgG antibody titre level (measured by the reference method) against graft survival 
 
However, there was no statistically significant difference in graft survival between the 2 
antibody level groups (p-value=0.074) as calculated by the Log Rank Mantel-Cox test.  
Chi-Square df Sig.
Log Rank (Mantel-Cox) 3.185 1 0.074
Breslow (Generalized Wilcoxon) 2.878 1 0.090
Tarone-Ware 3.093 1 0.079
Overall Comparisons
Test of equality of survival distributions for the different levels of AbLevel.
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Fig 18 shows the survival curves for High and Low antibody levels on the same samples but 
measured by the Tube IAT method used in the study. 
 
Figure 18 ABO IgG antibody titre levels (measured by the study Tube IAT method) against graft survival. 
 
There was also no statistically significant difference in graft survival between the 2 antibody 
level groups with significance level of p-value=0.074, similar to that calculated for the 
Reference method in Fig 17.  
 
When the study Bio-Rad IAT method was used to determine the antibody levels, the 
survival curves in Fig 19 were obtained for the High and Low antibody categories. 
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Figure 19 ABO IgG antibody level (measured by Bio-Rad IAT method) against graft survival 
 
There was no significant difference between graft survival in the 2 antibody groups, p-
value=0.315. However, the High antibody level group had longer cumulative survival 
compared to Fig 17 and 18. 
 
Survival curves were also prepared for High and Low antibody groups determined by the 








                                                                   Antibody Titration Methods 
Page 90 of 138 
 
 
Figure 20 ABO IgG antibody titre level (measured by study BioVue IAT method) against graft survival 
 
Study BioVue IAT was the only method that demonstrated statistically significant difference 
between the 2 antibody groups, p=0.025 and also, more patients were censored in the high 
antibody group than in Figs 17-19. This was also the only method that demonstrated no 
graft rejection nor censoring in the 5-year period. 
 
2.11.7 Managing ABO incompatible transplants with respect to each titration 
methodology investigated in 2.116 above. 
Use of any antibody titration method in ABOiRTx has accompanying cost implications. A 
method which underestimates the antibody titre would mean that patients will be 
transplanted before they are ready i.e. when their antibody levels are still high thus resulting 
in unnecessary cost and time wastage in trying to deal with transplant rejection. Conversely, 
the titration method that overestimates titres will result in pre-transplant over preparation of 
patients or total exclusion from transplantation for patients that could either proceed to 
transplantation with minimal preparation.  
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The titration methods were therefore assessed for cost-effectiveness by reviewing the 
decisions made based on each method and the transplant outcome. This would give an 
indication of patients that were possibly transplanted before they were ready (and vice 
versa). An ideal antibody titration method will give an accurate titre thus allowing the correct 
decision to be made and appropriate allocation of resources. 
 
In the results obtained in 2.11.6, there was no significant difference in graft survival between 
high and low antibody levels as measured by Reference IAT, study Tube IAT and study Bio-
Rad IAT although the low antibody group had the lowest cumulative graft survival and also 
had the most censored patients who did not experience graft rejection. The study BioVue 
IAT method was the only method that categorised the antibody levels to cause a significant 
difference in the graft survival of the patients investigated.  
 
2.12 Maximum pre-transplant/Baseline ABO antibody titres and plasma exchange in 
the 30 study patients 
Table 22 shows the baseline (maximum ABO antibody measured before plasma exchange) 
and pre-operative (maximum ABO antibody measured after effective plasma exchange 
cycles) antibody titres of the study transplant recipients. The titration shown in the table was 
performed by the Reference Laboratory (Red Cell Immunology Laboratory at Colindale) 
therefore, information presented is retrospective. The same samples used pre-
transplantation were tested using the 6 antibody titration methodologies chosen in this study 
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Plasma exchanges were carried out for each recipient until the ABO antibody titres were 
≤64. However, for 2 of the recipients (1 and 23), transplant was carried out at a combined 
IgG + IgM titre of 16 but IgG only titre of 4. The Reference laboratory used Bio-Rad DRT 
with untreated plasma to measure Combined IgM+IgG titre and DTT treated plasma for the 
































1 256 (8) 64(6) 16(4) 4(2) 10 
2 128(7) 64(6) 4(2 Neat (0) 11 
3 128(7) 128(7) 2(1) Neat (0) 9 
4 16(4) 4(2) Neat (0) Neat (0) 7 
5 16(4) 128(7) Neat (0) Neat (0) 6 
6 128(7) 4(2) 4(2) 2(1) 8 
7 16(4) 4(2) Neat (0) Neat (0) 2 
8 128(7) 2(1) Neat (0) Neat (0) 8 
9 64(6) 16(4) 2(1) Neat (0) 7 
10 128(7) 128(7) 2(1) Neat (0) 11 
11 512(9) 256(8) 8(3) 8(3) 15 
12 128(7) 64(6) 4(16) Neat (0) 8 
13 16(4) 16(4) 2(1) Neat (0) 5 
14 64(6) 64(6) 8(256) 2(1) 4 
15 64(6) 64(6) 4(2) Neat (0) 4 
16 128(7) 32(5) 8(3) 2(1) 8 
17 128(7) 64(6) 4(2) Neat (0) 9 
18 64(6) 2(1) 8(3) Neat (0) 4 
19 16(4) 4(2) Neat (0) Neat (0) 2 
20 2(1) 32(5) 8(3) 2(1) 3 
21 8(3) 32(5) 8(3) Neat (0) 3 
22 8(3) 64(6) 4(2) Neat (0) 4 
23 512(9) 128(7) 16(4) 4(2) 12 
24 2(1) 64(6) Neat (0) Neat (0) 2 
25 2(1) 128(7) Neat (0) Neat (0) 8 
26 128(7) 128(7) 4(2) Neat (0) 10 
27 128(7) 128(7) 2(1) 2(1) 11 
28 8(3) 32(5) Neat (0) Neat (0) 3 
29 16(4) 4(2) Neat (0) Neat (0) 2 
30 64(6) 64(6) 2(1) Neat (0) 4 
Figures in parenthesis represent the respective titres expressed as logarithm2  
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Pearson’s correlation was carried out to investigate for relationships between the variables 
“Combined baseline IgG and IgM antibody titre”, “baseline IgG only antibody titre” and  
“number of Plasma exchanges” carried out to reduce the titres of the measured antibodies. 
Data is presented in Table 23. 
 
Table 23 Investigation of Correlation between antibody titre and Number of Plasma Exchanges 
 
 
There was significant evidence of a relationship between Combined baseline IgG+IgM  
antibody titre and Number of Plasma Exchanges (r=0.740, p<0.05) and also between 
baseline “IgG only” antibody titre and Number of plasma exchanges (r=0.495, p=0.005) 
although the latter had a weaker correlation coefficient.  
 
Figure 19 demonstrates that, in general, as the baseline IgG and IgM ABO antibody titre 

























  0.318 0.000 









0.318   0.005 













N 30 30 30 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Figure 21 Pre-transplant Baseline ABO antibody titres (by the Reference Laboratory DRT and IAT methods) against number of plasma 
exchanges 




































                                                                   Antibody Titration Methods 
Page 95 of 138 
 
2.13 A comparison of the titration methods investigated in this study against the 
titration methods used by the Reference Laboratory at the time of transplantation 
Table 24 shows combined IgM+IgG titres and IgG only titres measured by the different 
methods, IAT methodologies used in the study (and the method used by the Reference 
Laboratory at the time of transplantation), against the number of respective plasma 
exchanges.  
Table 24 ABO antibody titres (as measured by different titration methodologies) against number of Plasma Exchanges 
 
*3 samples could not be processed using the DTT treatment method for IgG due to sample insufficiency. These samples 
were therefore excluded from the comparison between Plasma exchanges and IgG titre by Bio-Rad method using the IgG 
Bio-Rad with DTT treatment method chosen for this study. Data shown in shaded columns was obtained from the current 
study while the rest was performed by the reference laboratory at the time of transplantation. 
 
The results in Table 24 are displayed in a scatter plot in Fig17 in order to demonstrate the 


























1 10 8 9 5 8 9 9
2 11 7 6 6.5 8.5 9.5 5
3 9 7 7 4.5 5.5 7 7
4 7 4 2 8.5 8.5 9 1
5 6 4 7 7 9 10 6
6 8 7 2 9 9 10.5 4
7 2 4 2 5.5 6 6 2
8 8 7 1 8 9 9.5 2
9 7 6 4 4.5 4.5 7 4
10 11 7 7 5.5 5.5 7.5 7
11 15 9 8 7 7 9 7
12 8 7 6 5.5 7 8 4
13 5 4 4 8 8 8 4
14 4 6 6 10 8 8 Not done*
15 4 6 6 10 9 8 4
16 9 7 6 7 9 10 6
17 3 3 5 4.5 4.5 7 5
18 4 3 6 5.5 5.5 7.5 6
19 12 9 7 7 7 9 7
20 2 1 6 5.5 7 8 Not done*
21 10 7 7 6.5 8.5 9.5 7
22 11 7 7 4.5 5.5 7 5
23 4 6 6 9 9 10.5 4
24 4 6 1 4.5 4.5 7 1
25 2 4 2 5.5 5.5 7 Not done*
26 2 2 4 2 6 6 3
27 7 4 2 4.5 4.5 7 4
28 6 4 7 5.5 5.5 7.5 6
* Test not performed due to sample insufficiency
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Figure 22 A comparison of the number of plasma exchanges against ABO antibody titres measured by different methodologies. A line 
of best fit was drawn for each methodology to demonstrate the correlation between Log2 of ABO antibody titres and number of 
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(DTT treatment)
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By inspection, the IAT titre by the reference laboratory method and that by the Bio-Rad 
method with DTT treatment showed comparable correlation with the associated number of 
plasma exchanges. DRT titre by tube IAT and DRT by Bio-Rad IAT also showed a similar 
trend of weak but positive correlation with the number of plasma exchanges.  
DRT titre by BioVue IAT method had the highest overall number of plasma exchanges while 
the Bio-Rad IAT (with DTT treatment) had the lowest. The correlation and significance 
values for each methodology are shown in Table 25 below. 
 
Table 25 Correlation between Number of Plasma Exchanges and the antibody titre measured by each titration method 
Titre obtained by each titration 
methodology against the 






DRT titre by Reference laboratory 0.826 0.001 
IAT titre by Reference Laboratory (DTT 
treatment) 0.489 0.013 
DRT titre by Tube IAT 0.109 0.604 
DRT titre Bio-Rad IAT 0.175 0.402 
DRT titre BioVue IAT 0.401 0.047 
IAT titre Bio-Rad (DTT treatment) 0.574 0.003 
 
There was strong positive correlation between the number of plasma exchanges and the 
DRT titre measured by the reference laboratory (r=0.826, p=0.001) and moderate 
correlation when Bio-Rad IAT with DTT treatment was used (r=0.574, p=0.003). 
 
2.14 Implications of the differences in titration methodologies and Plasma Exchange 
in this study 
 As the only meaningful linear correlation with number of plasma exchanges was found 
between DRT titres measured by the Reference laboratory method and Bio-Rad IAT 
method with DTT treatment, predictions using regression equations could only be 
performed for these 2 methods. 
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The table below shows a comparison between the number of plasma exchanges that were 
performed as informed by titration results from the reference laboratory method (DRT titres) 
and the predicted plasma exchanges if the IAT method by Bio-Rad (with DTT treatment) 
method was used.  
Table 26 Number of Plasma exchanges as determined by antibody titre according to each titration methodology 
DRT titre (Log2) 
by Reference  
laboratory 
Number of Plasma  
Exchanges as 
determined by the 
Reference laboratory 
method 
IgG titre (Log2) 
(DTT treatment) by Bio-
Rad 
Number of Plasma  
Exchanges as 
determined by the 
Bio-Rad IAT 
method with DTT 
treatment 
8 10 9 6 
7 11 5 4 
7 9 7 5 
4 7 1 3 
4 6 6 4 
7 8 4 4 
4 2 2 3 
7 8 2 3 
6 7 4 4 
7 11 7 5 
9 15 7 5 
7 8 4 4 
4 5 4 4 
6 4 4 4 
7 9 6 4 
3 3 5 4 
3 4 6 4 
9 12 7 5 
7 10 7 5 
7 11 5 4 
6 4 4 4 
6 4 1 3 
2 2 3 3 
4 7 4 4 
4 6 6 4 
 
The mean number of plasma exchanges by DRT titre Reference laboratory method and by 
Bio-Rad IAT with DTT treatment was 7.320 and 4.080 respectively.  
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A paired t-test showed that there was a significant difference between the plasma 
exchanges measured by the 2 methods (p<0.005). 
These results demonstrate that if the Bio-Rad IAT method had been used to guide pre-
transplantation decision-making then significantly less plasma exchange cycles would have 
been required compared to the Reference laboratory DRT method. 
 
2.16 Discussion  
Comparison across IAT and DAT methods: The pilot study demonstrated good 
reproducibility and hence reliability of each of the selected titration methods through the 
pilot study. A major advantage of this study was that all titrations were carried out by one 
operator and hence no inter-operator variation considerations were necessary. This is one 
of the main issues which currently makes inter-laboratory comparison of titres unideal. 
However, despite one operator using all 6 methods, there was a wide variation in the results 
obtained on a set of 10 samples tested during the pilot study which suggested that there 
were other factors inherent in each method that resulted in the observed variation. This 
further confirmed this difference in results as discussed in Section 1.15.1. The variation in 
titres in the 10-sample pilot study informed the calculation of an ideal sample size of 50. 
This proved to be complex as there had not been any prior studies that looked at 6 titration 
methodologies with no agreed gold standard for comparison. Therefore, the calculation 
involved pairwise comparison of the 6 methods to determine level of variation within and 
across tests. This study may have set precedence for other similar subsequent studies in 
the area of antibody titration. 
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Participation of this study in the UK NEQAS ABO antibody titration pilot exercise further 
validated the reliability of the methodologies used as the results were either identical or 
within 1 dilution (or titre step) of the method median. 
The pilot study showed that there was a significant difference between the DRT methods 
except between Bio-Rad DRT and BioVue DRT.  
There was also an overall statistically significant difference between the IAT methods used 
in the pilot study except between Tube IAT and Bio-Rad IAT (p=0.316). An overall 
assessment across all methodologies (both IAT and DRT) in the pilot revealed a significant 
difference (p=0.026) with the following agreements between methods upon pairwise 
investigation: Tube IAT/Tube DRT, Tube IAT/Bio-Rad DRT, Tube IAT/BioVue IAT, Tube 
DRT/BioVue IAT, Bio-Rad IAT/BioVue IAT, Bio-Rad IAT/BioVue DRT, BioVue DRT/BioVue 
IAT. 
However, when all study samples were considered, using multivariate analysis overall 
significant difference across all methods (IAT and DRT) was observed (p=0.000) as seen in 
the pilot. However, upon pairwise comparisons, the only pairs of methods that showed 
agreement were Tube IAT/Tube DRT, Tube DRT/Bio-Rad IAT and Bio-Rad DRT/BioVue 
IAT. The differences in the results between pilot and full study was most likely due to the 
differences in the sample sizes, however, agreement between these methods out of all the 
possible pairs of methods shows that only methods within each pair can be used 
interchangeably and not across pairs.  
The pairs of methods in agreement seem to be IAT against DRT each. Ideally, the 
agreement should have been between techniques that use the same methodology as in 
general IAT techniques detect IgG and very little IgM antibodies compared to DRT 
techniques which seem to detect more of the IgM than IgG.  
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A study at John Hopkins hospital(124) reported that tube DRT ABO antibody titres  were not 
necessary and do not offer any more data pertinent to clinical decision-making than IAT 
titres and when they compared DRT titres to gel card IAT they found that 86% of the results 
were identical. They concluded that the DRT method and IAT by gel card method were 
comparable, but the gel card method reduced turnaround times through reduced incubation 
times and performing the titrations in batches(124). However, in this study, there was no 
overall comparability across all titration methodologies although there were individual pairs 
of methodologies that demonstrated a level of agreement. 
 Other studies that looked at only 2 methodologies e.g. Cho et al(125)  reported that column 
agglutination technology was more sensitive compared to the tube technique. However, 
they used the immediate spin technique for their tube method which does not have an 
incubation step instead of the more sensitive 30 min room temperature incubation version, 
so this may have affected the sensitivity of their tube method. 
 It is also important to note that with card agglutination techniques that utilise glass beads 
e.g. in the case of the BioVue method, there is a tendency to obtain higher ABO antibody 
titres (101). This was noted initially in the pilot study results whereby the average titre 
obtained by the BioVue IAT method was higher. Tanabe(104) observed that bead column 
agglutination method  demonstrated  worse reproducibility with high maximum titre than gel 
column agglutination method and also that serum to cell ratio is slightly higher in column 
agglutination methods using glass beads. Serum -cell ratios are determined and proposed 
by manufacturers and are different depending on column ingredient, this information is 
essential so that a distinction is made between methods that use different specifications 
when comparing target levels of ABO antibody titres. 
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It may be argued that in cases where a standard method has been found, a method that 
reasonably overestimates titres is preferable as plasma exchange can then be carried out 
accordingly, unlike when a method underestimates and patients are possibly underprepared 
for transplant. 
 
Lack of consensus on the definition of the reaction grade for the titration endpoint has been 
another source of variation in ABO antibody titration surveys. In this study a 1+ 
agglutination reaction was used as the endpoint because of its unambiguity compared to a 
weaker (w+) reaction which is less discernible and subjective between different operators. 
 Use of different definitions of endpoints makes comparisons across studies difficult e.g. 
Cho et al (125) used a ‘w+’ endpoint instead of the ‘1+ grade used by Kang’s study (101)  
and this clearly causes disparity in results obtained.  
Some previous studies have reported that the titres obtained with gel column IAT are 
comparable to those obtained with tube IAT(124). In Kang’s study (101), they looked at 3 
methods without DTT treatment which showed different detection capabilities  of the IgG 
type of ABO antibody according to the ABO group. 
Card agglutination technique has been proven to reduce the inter-laboratory variations in 
ABO antibody titres as well as the turnaround times. However, given the requirement of 
expensive reagents and the financial limitations, its use as a routine method is limited in 
some countries.  
 
It is also important to note that the monospecific antihuman (AHG) used in the gel card 
technique could cross-react with IgA and IgM isotypes as well as with complement 
components. 
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Hence the tube or gel techniques used with the AHG can potentially overestimate the IgG 
type of ABO antibody compared to flow cytometry that uses an isotype specific antibody. 
 
Lack of overall agreement between methods suggests that, for standardisation purposes, 
the proposed method has to be chosen from the identified pairs in agreement.  
The study showed significant differences in the results obtained by different titration 
methodologies on the same set of samples. These methodologies are in current use across 
the world and being utilised to inform patient management regarding pre- and post- 
ABOiRTx treatment.  
 
DTT treatment: Shirey et al (124) reported that ABO antibody titres measured using AHG 
are critical for clinical management.  
However, the IgM isotype of ABO antibody can interfere in the detection of the IgG type of 
ABO antibody when DTT treatment of plasma is not used. This mainly affects blood groups 
A and B which mostly consist of the IgM type of ABO antibody. DTT treatment is needed to 
measure the exact IgG titration. However, the process of DTT treatment is cumbersome, 
time-consuming, and may even destroy the IgG. According to the ‘uniform procedure’ for 
ABO antibody titration suggested by the College of American Pathologists, the DRT tube 
test can be converted to the AHG phase after 30 mins of RT incubation without DTT 
treatment. Therefore, if DTT has not been used for titration, of the IgG type of ABO 
antibody, results need to be reported as a measure of ‘total antibody’ and not IgG. 
Alternatively, the gel card test is better in detecting the IgG type of ABO antibody and may 
be used instead.  
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In Kang et al’s study(101) however, three methods using sera without DTT treatment 
showed different detection capabilities of the IgG type of ABO antibody according to the 
ABO blood group. Therefore, caution should be exercised when interpreting the detection of 
the ABO antibodies. 
 
Standardisation of ABO antibody titration methodologies: ABO antibody titration by 
haemagglutination is a very simple, convenient and accessible method which, if all variables 
affecting this technique are appropriately controlled, it would be easier to compare, transfer 
patients across institutions and also perform metanalyses. Due to significant inter-laboratory 
variations in widely used tests for ABO antibody titre measurement, the use of card 
agglutination techniques has increased in recent years. However, some laboratories still 
use the tube haemagglutination technique and a few have begun to use flow cytometry. 
From Fig16, the 2 most popular titration methods “DRT standard” and “IAT standard”, would 
be most ideal for standardisation.  
Unfortunately, standardisation of antibody titres has continued to be elusive with proficiency 
testing still demonstrating large variations in titration results.  By using a detailed procedure 
and a weak positive endpoint (+w), the College of American Pathologists was able to 
reduce the interlaboratory variation (106). They also concluded that using a detailed and 
consistent laboratory method for antibody titres may render the current practice of repeating 
titres from a previous sample with the current sample unnecessary, because the variation of 
titres decreases over time. Furthermore, UKNEQAS and NIBSC are currently working 
together to develop lyopholised ABO antibody standards which can be used for proficiency 
testing and as references when setting up titrations. 
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The implications of not having a standardised assay include poor allograft, listing for paired 
exchange programmes unnecessarily and excessive desensitisation. Using a non-
standardised protocol causes considerable variability in the ABO titre targets used for 
clinical decision-making and may play a role in poorer allograft outcomes. There is no 
evidence yet to demonstrate effect of titre variation on clinical outcomes(105). Kumlien et 
al(112) conducted a  three-centre study whereby a standard method was compared to local 
results but no clinical outcomes were correlated with differences in titre values. This finding 
was also confirmed in the current study whereby no overall correlation was observed 
between graft outcome and the different types of antibody titration methodologies. This 
correlation may be difficult to objectively investigate unless all other variables, including 
immunosuppression regimen, number of dialysis sessions pretransplant etc. are reasonably 
controlled. 
The issue of A or B antigen densities on titration cells has not been investigated as a factor 
that might affect the antibody titration results. However, no difference in results was 
observed between different batches of titration cells when the same samples were tested.  
This is most likely due to the use of different donors pooled together in the manufacturing of 
titration cells which reduces the effect of biological variation. 
Baseline antibody titres: Some studies have indicated that high baseline anti-A/B IgG titre 
is a predictor for AMR (126) and poor long term allograft survival in ABOiRTx(78). 
However, most clinicians remain focused only on the target antibody titre (i.e. pre-transplant 
titre following antibody removal) and do not take into account the differences that may be as 
a result of the choice of the method used. This has constituted part of the problem in 
ABOiRTx because antibody titre has been considered as an arbitrary term assumed to have 
a definitive methodology for measurement and therefore thought to be standard across all 
institutions.  
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This has resulted in differences in outcome results thus making comparisons across studies 
difficult and making it hard to define an upper limit of antibody level at which transplantation 
is high risk. 
 
Shimmura et al (127) investigated if an immunosuppressive regimen involving the 
administration of tacrolimus, MMF and steroid, prior to transplantation would negate the 
influence of preoperative anti-A/B titres on graft survival. Their study indicated that the use 
of this regimen may result in a much better survival and eliminate the influence of 
preoperative antibody titres on graft outcomes. This was an important finding because the 
effect of baseline antibody titre will be rendered unnecessary if this finding was to be 
replicated in other studies. Nakagawa et al (128, 129) investigated the necessity of ABO 
antibody removal in ABOiRTx in 2 groups of patients, one did and the other did not undergo 
pre-transplant removal of ABO antibodies. They found no significant difference in graft 
outcome between the 2 groups and concluded that the most important consideration was 
the inhibition of de novo formulation of ABO antibodies rather than removal of preformed 
ones.  
 
However, due to different immunosuppressive regimens across institutions, it is difficult to 
make comparisons and confirm this finding without carrying taking into consideration all the 
immunosuppressive regimens used by different groups or rather without standardising 
treatment modalities across all ABOiKTx groups.  
 
In the current study, the results showed that the number of plasma exchanges was strongly 
correlated to the baseline (maximum pre-transplant titre).  
Therefore, accurate measurement of the baseline titre is critical to ensure the correct 
number of plasma exchange cycles are carried out.  
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The results in Section 2.14 showed that if the Bio-Rad method with DTT treatment used in 
this study had been used to guide plasma exchange, then significantly less plasma cycles 
would have been carried out compared to when the Reference laboratory DRT method was 
used at the time of transplant. This comparison between these 2 methods was made 
because they were the only methods that showed strong linear correlation to plasma 
exchange. Therefore, if any of the titration methods, currently in use in different institutions, 
will result in significantly different decisions with regards to PE then it is difficult to identify 
which one is ideal in the absence of a gold standard method. 
 
AMR and antibody titre: AMR may occur even if the pre-treatment level of ABO antibody is 
low. Although it can occur with any pre-transplant level, AMR is more likely when the ABO 
titre is greater than 1/256(107-109). In this study, no statistically significant difference was 
observed between ‘High’/ ‘Low’ ABO antibody levels and graft survival when Reference 
laboratory IgG, study tube IAT and study Bio-Rad IAT were used (p>0.05). The only 
statistically significant difference in survival was noted between the 2 antibody categories 
and graft survival when study BioVue IAT method was used (p=0.025).  
 
Overall, this might suggest that baseline ABO antibody titre is not associated with graft 
outcome or that, even if there may be an association, it is confounded by the antibody 
depletion interventions used pre- and post-transplant. Other groups like that of Montgomery 
(67, 70) at Jones Hopkins, used the pre-transplant baseline antibody level to decide on 
initiation of post rather than pre-transplant plasma pheresis. This was in contrast to other 
studies(130) who hold the view that an on-demand strategy for plasma pheresis guided by 
post antibody titres is ideal. 
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2.17 Conclusion 
Overall, the 6 ABO antibody titration methods in this study showed an overall statistically 
significant difference using ANOVA multivariate analysis although upon pairwise analysis 
association between the following pairs of methods were observed: Tube IAT/Tube DRT, 
Tube DRT/Bio-Rad IAT and Bio-Rad DRT/BioVue IAT. The absence of overall agreement 
between the titration methodologies meant that the methods cannot be used 
interchangeably. However, since in general, the pairs that showed agreement upon pairwise 
investigation seemed to be all combinations of IAT and DRT methodologies, a proposal to 
select column agglutination can be made. In this case a reasonable choice would be Bio-
Rad IAT which is reproducible and reasonably accessible to most laboratories even as a 
manual technique. Of the 2 column IAT techniques BioVue can be discounted because of 
its reported tendency to overestimate titres. 
DTT treatment of plasma is rather cumbersome and is more skill intensive and can easily 
be replaced by column agglutination which utilises anti-IgG for the measurement of IgG 
isotype. 
With regard to ABOiRTx, the number of plasma exchanges was closely linked to baseline 
ABO antibody titres, therefore objective measurement is required and can be achieved 
through standardisation of the proposed Bio-Rad IAT method that can be refined overtime 
and proficiency testing implemented across all centres for comparison and performance 
monitoring. 
No overall association was found between baseline ABO antibody titres and graft outcome. 
This was most likely due to the possible confounding use of plasma exchange and 
immunosuppression.
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Chapter Three: Measurement of IgG Subclasses 
3.0 Measurement of ABO antibody IgG subclasses 
Antibody titration described in Section 2 using haemagglutination methodologies does not 
discriminate subtype specific ABO antibodies and provides limited information on antibody 
isotypes or subclasses with respect to ABOiRTx. 
 
This part of the study is aimed at developing an ELISA (Enzyme Linked Immunosorbent 
Assay) method for the determination of IgG subclass profiles in order to correlate them to 
their respective clinical outcomes i.e. graft rejection or survival. In order to enhance the 
detection capability in the current study as frozen sample volumes were a limiting factor, the 
‘indirect’ as opposed to ‘direct’ ELISA technique was used. The following sections describe 
how this Indirect ELISA technique was developed for the measurement of ABO antibody 
IgG subclasses. 
 
3.1 Developing the ELISA technique for measurement of ABO subclasses 
An Indirect ELISA was developed in this study for the measurement of ABO IgG antibody 
subclasses. In this technique, micro-titre plates are incubated with antigens of interest, 
washed and blocked with Human Serum Albumin (HSA) to reduce non-specific binding of 
subsequent antibodies to the micro-titre plate. Samples suspected of having the antibody of 
interest (primary antibody) are added, washed and then followed by the addition of 
secondary antibody conjugated with enzyme. A substrate is then added which is catalysed 
by the enzyme on the secondary conjugate to produce a chromogenic signal which can 
then be detected either quantitatively or qualitatively. 
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This principle was used in developing the Indirect ELISA technique in this study and this 
involved coating polystyrene microtitre plates with blood group A or B neoglycoproteins 
(NGPs) conjugated to HSA i.e. A-HSA and B-HSA and optimising the concentrations of 
patients’ plasma, primary antibody and secondary conjugate. The method was modified 
from a similar procedure used at the Leslie Brent Laboratory in a separate study which used 
a direct ELISA technique with no secondary conjugate.  
The basic principle is illustrated in Figure 23. 
 
 
Figure 23 Illustration of Indirect ELISA technique  
Antigen is immobilised onto a microtiter plate and samples suspected of having antibody of interest are added. Plate is then washed 
and a secondary antibody conjugated to an enzyme added followed by the substrate which is then catalysed by the enzyme to 
produce a chromogenic signal. The signal is then detected and measured. 
 
 
Section 3.1 below shows details of the procedure and reagents used for the indirect ELISA 
developed for this study. 
 
3.2 Indirect ELISA protocol  
The ELISA technique for each subclass as optimised in Section 3.3 above was then used 
for measuring ABO IgG subclass levels. All samples were assayed in duplicate and the 
results obtained for each pair of microtiter plate were averaged. 
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A-HSA and B-HSA (Dextra Laboratories Ltd) were diluted in 0.1 M bicarbonate buffer, PH 
9.6 (4.24g Na2CO3, 5.04g NaHCO3) [“Coating Buffer”] to a concentration of 10µg/ml. 
(Human serum albumin) HSA was also diluted in 0.1M bicarbonate buffer, PH 9.6, to a 
concentration of 10µg/ml. 
50µl of A-HSA, B-HSA and HSA were added to appropriate wells in the ELISA plates 
(Polysorb, Nunc). The ELISA plates were incubated overnight at 4◦C. Following incubation, 
the ELISA plates were washed 4 times with phosphate buffered saline containing 0.05% v/v 
Tween 20 (PBS-T0.05%: 0.012M Na2HPO4, 0.003M NaH2PO4, 0.15M NaCl made up to 1 litre 
with dH2O and adjusted to PH 7). 
 
50µl of each sample was added to appropriate wells and the ELISA plates incubated at 
room temperature for 45 min-1 h. The ELISA plates were then washed 4 times with PBS-
T0.05%. Rabbit antihuman globulin (RAH)-IgG1, RAH -IgG2, RAH -IgG3 and RAH-IgG4 
(Sigma-Aldrich) were diluted (as optimised in Section 3.3) with PBS-T0.05% and 50µl of each 
subclass specific antibody was added to appropriate wells. The ELISA plates were then 
incubated at RT for a further 1h, after which the plates were washed 4 times with PBS-
T0.05%. 50µl of mouse antirabbit globulin conjugated to horse radish peroxidase (HRP)  
(Sigma-Aldrich) diluted with PBS working buffer, PH 7.4 (16.7g Na2HPO4, 5.70g NaH2PO4) 
(as optimised in Section 3.3) as added to all wells and incubated for a further 30 minutes 
followed by washing 4 times with PBS-T0.05%.    
To develop the assay, Orthophenylene diamine (OPD) substrate (Sigma-Aldrich) was 
prepared using SigmaFast kit (Sigma-Aldrich) by dissolving 1 tablet of OPD and 1 of H2O2 
in 20ml of de-ionised water. 50µl of prepared substrate was added to each well and the 
reaction allowed to develop for 5-10 minutes. The reaction was then stopped by the addition 
of 50µl of 0.5M H2SO4 (BDH) to each well.  
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Absorbance measurements (Optical density-OD) were determined at 492nm using a 
(Anthos Labtec Instruments, Anthos 2000) plate reader. (This is procedure is illustrated in 
Fig 23)  
 
It is important to confidently define a negative value in a chosen assay. A positive optical 
density (OD) on an ELISA readout includes binding to the specific antigen, binding to HSA, 
additional non-specific binding and the OD of the ELISA plate. In the NGP ELISA it an 
essential initial step to subtract the background values obtained from either binding to HSA 
or the OD obtained from the binding to the neoglycoprotein. In the neoglycoprotein (NGP) 
ELISA a sample was considered negative when the mean background OD +3 SD (Standard 
deviation) of HSA subtracted from the OD obtained against the neoglycoprotein was zero or 
less i.e.  
(mean NGP OD)- (mean OD HSA +3SD) = “True OD” of antibody binding. 
 
To obtain the OD HSA+3SD ELISA plates were coated with HSA and “normal” background 
binding established by incubating sera from several individuals in duplicate and establishing 
the mean background HSA and mean and mean SD. To establish background binding for 
each antibody isotype (IgG1, IgG2, IgG3 and IgG4), ELISA plates were coated with HSA at 
10µg/ml. Sera from a number of individuals was used as shown for one patient below: 
Individual 1: serum was applied to 2x24 wells on HSA-coated ELISA plates and incubated 
as described above with RAH-IgG1/HRP, RAH-IgG2/HRP, RAH-IgG3/HRP and IgG4/HRP. 
For each plate and for each individual, 12 duplicate pairs of readings for each HSA 
duplicate were obtained. For each HSA pair, the mean OD was obtained, giving in total 12 
mean ODs (A).The mean (X) of these 12 means (A) and the SD of these 12 means (Y) was 
obtained. This process was performed on each of the study patients used and for each 
antibody class.  
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Once all readings were obtained, the mean SD (Z) of the mean SDs (Y) was obtained. This 
was the value that was then used in the NGP ELISA. 
 
When an NGP ELISA was performed, 4 readings were obtained for each individual – 2 
neoglycoprotein ODs and 2 HSA ODs. The mean OD for each duplicate was obtained. 
If the conjugates were conjugated to HSA and IgG was being investigated, the mean OD 
obtained for HSA was then multiplied by 0.075 to obtain the HSA SD.  The value was 
multiplied by 3 to give a final value that was then subtracted from the mean neoglycoprotein 
OD. This was performed for all study subjects. 
 
3.3 Optimisation of the ELISA technique 
During the development of the ELISA methodology for the detection of the ABO IgG 
antibody subclasses, reagent volumes and concentrations had to be optimised to ensure 
detectability and cost effectiveness of the procedure. For this purpose, the checkerboard 
technique (CBT) method was used, and the optimisation process involved testing different 
dilutions of the reagents and plasma used in order to determine the optimal concentrations 
using the least amount of reagent and plasma but yielding a signal strong enough to be 
detected. 
The need to use the optimal amount of antigen coated wells that will successfully bind to 
antibodies, which in turn can be detected with an optimal amount of anti-species conjugate. 
In the CBT method, only 2 variables can be titrated in one assay and the principal 
considerations are: 
 That enough antigen is available for antibody binding so as to prevent wastage 
through adding concentrations of antigen that are too high, thus causing wells to 
receive a large excess of antigen compared with the amount needed to fill available 
plastic sites. 
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 That the amount of the conjugate is optimised to avoid high non-specific 
backgrounds and to allow the detection of all bound antibody molecules to give the 
required analytical sensitivity expected. 
Figure 24 shows an illustration of the CBT method whereby dilutions of antigen and serum 
containing antibodies are tested against a pre-titrated secondary conjugate. 
 
Figure 24 Illustration showing a basic example of the Checkerboard technique for ELISA Optimisation. 
 
Optimisation also assesses the effect of diluting negative sera on an assay to establish the 
background readings of such antisera at various dilutions. 
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As part of the optimisation process, different concentrations of plasma were prepared in 
PBS working buffer and different concentrations of both the primary antibody and secondary 
conjugate were prepared. 
The optimisation process was carried out for all 4 IgG subclasses and the results are shown 
in Figs 23-26 incl. 
 
3.3.1 ELISA Optimisation for the measurement of IgG1 subclass 
Different dilutions of Rabbit antihuman globulin IgG1 (RAH)-IgG1 were set up against 
dilutions of pooled plasma and a set dilution of the secondary conjugate at 1 in 5000 
dilution. 
 
Figure 23 ELISA Optimisation for IgG1 subclass measurement (Different dilutions of anti-IgG1 and serum but secondary conjugate at 1 
in 5000) 
 
From these results, the ideal dilutions of reagents for the IgG1 subclass ELISA were as 
follows:  Plasma (0.01=1 in 100), anti-IgG1 (1 in 2000) and secondary conjugate (RAH-






















Inverse of serum dilution
1000/5000 2000/5000 4000/5000 5000/5000
                                                                                 IgG Subclass Measurement 
Page 116 of 138 
 
3.3.2 ELISA Optimisation for the measurement of IgG2 subclass 
 
 
Figure 24 ELISA Optimisation for IgG2 subclass (Different dilutions of anti-IgG2 and serum against secondary anti-IgG at 1 in 1000 
dilution) 
The selected ideal dilutions of reagents for the IgG2 subclass ELISA were as follows:  
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3.3.3 ELISA Optimisation for the measurement of IgG3 subclass 
 
 
Figure 25 ELISA Optimisation for IgG3 subclass 
 
The selected ideal dilutions of reagents for the IgG3 subclass ELISA were as follows:  
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3.3.4 ELISA Optimisation for the measurement of IgG4 subclass 
 
 
Figure 26 ELISA Optimisation for IgG4 subclass 
 
The selected ideal dilutions of reagents for the IgG4 subclass ELISA were as follows:  
Plasma (0.01=1 in 100), anti-IgG2 (1 in 8000) and secondary conjugate (RAH-IgG/HRP) (1 
in 5000).  
 
Once all the optimisations were completed, the respective dilutions of antibodies were then 
applied to the method, as detailed previously in Section 3.2. 
 
3.4 Testing patient samples for IgG subclasses 
Once the method was established, the ABOiRTx patient samples were then tested for IgG 
antibody subclasses. Only 9 out of the 30 study samples had sufficient plasma to carry out 
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Table 27 ABO IgG antibody subclass status against ABO blood group and Transplant outcome on 9 study samples 
 IgG antibody Subclass    
Case Number IgG1 IgG2 IgG3 IgG4 Recipient's 
 Blood group 
Graft 
Outcome 
1 Pos Pos Neg Neg O Rejected 
2 Pos Pos Pos Neg O Rejected 
3 Pos Pos Pos Neg B Rejected 
4 Pos Pos Neg Neg A Censored 
5 Neg Pos Pos Neg A Censored 
6 Neg Pos Neg Neg B Censored 
7 Neg Pos Neg Neg B Censored 
8 Pos Neg Pos Neg O Rejected 
9 Pos Pos Pos Pos O Rejected 
 
The results show that 5/9 patients whose samples were tested demonstrated graft rejection. 
In all cases of graft rejection, 4/5 of recipients had both IgG1 and IgG 2 subclasses. In fact, 
IgG1 and IgG2 subclasses were detected in 5/9 of the patients and, of these, 4 experienced 
graft rejection. The 5th patient to undergo rejection tested for IgG1 and IgG3 only. Only in 1 
case of the 4 patients that did not experience rejection (censored) were both IgG1 and IgG2 
subclasses detected and these subclasses these were not found in samples from the 
remaining 3 patients that did not experience rejection.  
 
IgG4 subclass was only detected in 1/9 patient samples and this patient also experienced 
graft rejection. Furthermore, this patient tested positive for all subclasses of IgG (IgG 1,2 
and 3). 
 
IgG3 was detected in 4/5 of the graft rejection cases but in only 1/4 of the censored cases. 
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A Chi-Square test was used to check for any association between graft outcome and ABO 
IgG subclass. Due to the small sample size used, expected frequencies in the Chi-Square 
contingency table were less than 5, therefore Fisher’s Exact test version of Chi-Square was 
used. The results are shown in Table 28. 
Table 28 Significance levels of ABO antibody IgG Subclass status against transplant outcome of 9 study samples 
IgG Subclass against graft outcome Test statistics and significance 
IgG1 χ2 (1) =5.625, p=0.048 
IgG2 χ2 (1) =0.900, p=1.000 
IgG3 χ2 (1) =2.723, p=0.206 
IgG4 χ2 (1) =2.057, p=0.358 
 
There was no association between IgG2, IgG3 and IgG4 subclasses and graft outcome. 
The only association with graft outcome was noted with the IgG1 subclass.  
No association was found between IgG subclass and ABO blood group of the recipients as 
shown in Table 29. 
Table 29 Significance levels of ABO IgG antibody subclass status against respective ABO blood groups on 9 study samples 
IgG Subclass against ABO blood 
groups (A, B and O) 
Test statistics 
and significance 
IgG1 χ2 (2) =2.625, p=0.269 
IgG2 χ2 (2) =1.406, p=0.495 
IgG3 χ2 (2) =1.238, p=0.539 
IgG4 χ2 (2) =5.143, p=0.273 
 
However, the sample size for this part of the study was small and hence statistical power is 
too low to draw conclusive deductions on this association. The study investigations were 
limited to the available volumes of frozen plasma samples. 
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3.5   Discussion  
The results in this study showed that in all cases of graft rejection investigated, 4 out of the 
9 recipients had both IgG1 and IgG 2 subclasses. This corresponds well with Lee et al’s 
study(114) where they found that, using flow cytometry, the baseline level IgG1 and 2 were 
the predominant subclasses in ABOiRTx. However, another study has shown that IgG2 is 
predominant in cases of ABO incompatibility rather than IgG3 (117). 
 
There was no association between IgG2, IgG3, IgG4 subclasses (as individual entities) and 
graft outcome. The only association with graft outcome was noted with the IgG1 subclass 
disregarding presence of the other subclasses. 
 
IgG2 was detected in 4/4 of the patients who did not experience graft rejection. This may 
support the hypothesis put forward by Kirk et al(85) who suggested that accommodation of 
graft is related to a shift within the IgG isotype to the IgG2 subclass which is considered less 
efficient at activating complement. This subclass competitively inhibits the binding of the 
other subclasses known to be more cytotoxic. This concept can only hold true if this 
antibody is consistently present pre- and post-transplant and must demonstrate some high 
level of resistance to plasma exchange. 
 
IgG3 was detected in 4 of the graft rejection cases and in 1 of the censored cases. This 
subclass is thought to be the one mainly responsible for increased risk of HAR as it is highly 
effective at activating complement. However, the sample size was very small to make a 
substantive conclusion regarding this subclass and graft survival although this subclass was 
found in 4 out of 5 patients who experienced graft rejection in this study. 
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IgG4 is normally present in the least concentration in humans and increases are normally 
associated with chronic antigenic stimulation (131, 132). This isotype was detected in only 1 
out of the 9 cases in this study. This could be because no antigenic stimulation had been 
introduced yet through graft transplant and therefore the levels were still low pre-transplant. 
It is also interesting that this was in a patient with rejection which might suggest that the IgG4 
subclass level may have increased after transplantation and was possibly involved in graft 
rejection. However, it is also possible that the patient may have had other comorbid factors 
that may have resulted in graft rejection. 
This brings about the question of the relevance of testing subclasses pre-transplant when the 
patient will receive immunosuppression to suppress the effects (if any) of these preformed 
antibodies. It may be more useful to look at the ABO IgG antibody subclass profile post-
transplant in order to monitor for any changes that might be suggestive of graft rejection 
activity.  
 
When considering blood group specificity, no association was found between ABO IgG 
subclass and ABO group, however, the sample size was too small to make a generalised 
conclusion due to lack of fair representation across all ABO blood groups. 
 
The sample size for testing with the IgG subclass ELISA was limited by the available 
sample volumes as the study relied on historical samples that were frozen and had been 
kept for many years. Therefore, out of the 30 ABOiKTx samples, only 9 had sufficient 
volume to perform both antibody titration and IgG subclass investigation. A prospective 
study will therefore be ideal as samples and relevant study information can be collected 
contemporaneously.  
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Apart from sample adequacy, sample integrity in terms of IgG subclass activity after a 
prolonged period in frozen state could not verified as no measurements had been 
conducted pre-transplant so there was no basis for comparison.  
 
Developing an ELISA is a process is quite cumbersome and requires skill and experience 
and therefore may not be suitable for a routine Blood Transfusion laboratory. Several runs 
with different dilutions of reagents and plasma were performed to achieve reasonable 
optimisation before the final method for each isotype was decided upon. 
 
3.6 Conclusion  
The aim of this part of the study was to develop an ELISA method that would determine the 
presence or absence of IgG subclasses in renal transplant patients and determine if there 
was any association with graft outcome 
The objectives of this section of the study were achieved but the only drawback was the 
number of samples available for ELISA testing. However, the indirect ELISA technique 
developed in this study can be used in other prospective studies with larger sample sizes for 
more statistical power. 
Nevertheless, based on this sample size, it was discovered that most of the cases that 
experienced graft rejection had a combination of IgG1 and IgG2 subclasses present. 
No association was found between ABO IgG2, IgG3 and IgG4 as individual entities and graft 
outcome. IgG1 was the only antibody that demonstrated association with graft outcome. 
IgG2 was detected in 4 out of 9 cases who did not experience graft rejection which suggests 
a confirmation of the protective nature of this subclass through reduced effectiveness in 
activating complement. 
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IgG3 was detected in 4/5 out of the graft rejection cases which also confirms one of its 
features which is efficiency in activating complement. 
IgG4 was detected in 1 out of the 9 cases. This subclass is usually found only in low quantities 
in healthy individuals. However, the sensitivity of the ELISA methodology used in this study 
may be queried in light of this result.  
Indirect ELISA is considered to be a very sensitive method and therefore able to detect the 
intended analyte once test has been developed and optimised. In this study, the ELISA 
methodology for detecting IgG4 was tested against a pooled plasma sample and was proven 
to be able to detect this subclass.  
No association was found between the ABO IgG subclasses and patients’ blood groups, 
however, a larger sample size is required to further establish this finding. 
   
3.7 Future Work 
Flow cytometry and ELISA 
It is evident that although haemagglutination methods for quantifying ABO antibodies are 
ideal in terms of accessibility, cost and simplicity, they are not easy to standardise. It may 
take a very long time before a standard method is agreed upon and proficiency surveys 
conducted to monitor performance across centres. 
 
Techniques like flow cytometry and ELISA, though expensive and therefore out of reach of 
many laboratories, may provide an ideal opportunity for standardisation. Flow cytometry can 
be used to measure ABO antibodies through binding to natural ABO antigen on the red cells 
and offers more specificity and sensitivity. This may be an advantage over ELISA which 
utilises synthetic immobilised ABO antigens. 
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Both methods can be used to investigate the binding of different anti-A/B isotypes and 
subclasses through the use of specific secondary antibody.  
 
The dynamics of ABO IgG antibody subclasses need to be investigated further (using larger 
sample sizes) in terms of pre- and post-transplantation periods while taking into account 
other factors like standardised immunosuppression regimens. 
 
Therefore, if upon further studies, these methods prove to be objectively essential in the 
area of ABOiRTx, they may have to be performed at centralised laboratories for cost 
effectiveness. 
 
Surface Plasmon Resonance (SPR) 
ABO antibodies can be quantified using another uncommon method called SPR used by 
Kimura et al (133). This method measures changes of the physical properties of ABO 
antibody/antigen complexes of which the antigens are immobilised on a sensor chip. This 
technique can be instrumental in determining the antibody affinity as opposed to the just the 
quantity as measured by other methods. This method can therefore be utilised to predict the 
strength of interaction between ABO antibodies and the graft and because it is rather 
expensive, can be used pre-transplant to determine level of risk where pre-transplant PE 
may be indicated by the presence of high affinity antibodies.  
 
ABH-glycan Microarray  
Another specialised methodology was proposed by Jeyakanthan et al (26) which uses ABH-
glycan microarray for the determination of donor-specific ABO antibodies in ABOiRTx.  
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This method offers the advantage of being able to provide a profile of recipient antibodies 
directed against ABO antigen subtypes expressed in the donated organ (e.g. A types -I-VI, 
B types I-VI and H types I-VI)(22). This type of study would be instrumental in predicting 
graft outcome based on the ABO-glycan profile thus enabling assessment of patients 
against donors. Due to the accuracy offered by this approach to the identification of pre-
formed ABO antibodies to ABO antigen subtypes, it is possible to avoid unnecessary 
interventions through aggressive PE and immunosuppression.
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Chapter Four: My journey on the DBMS and the project 
 
The Professional review and development module in the 1st year was quite useful in setting 
up objectives and also identifying areas of strengths and weaknesses. The PGS development 
programme helped me to address my weaknesses through various courses throughout the 
DBMS programme. Through this system I learnt presentation, Advanced MS Word, SPSS, 
writing your thesis and how to publish articles etc. These are all skills that I have been using 
in different areas e.g. at work and other activities. 
4.0 Presentations 
I have had the opportunity to present my findings at different stages of the study and have 
received useful feedback. As a result, I have improved on my presentation skills and I now 
apply this experience regularly e.g. in meetings, delivering lectures or training sessions.  
Class presentations and group activities during the programme were quite useful as I 
managed to learn from my colleagues from different disciplines. The opportunity to interact 
with them and share ideas and skills helped me to improve on my presentation skills 
particularly in articulation of ideas and dealing with questions. The group activities were 
instrumental in that they taught me group dynamics and how to function in a group with 
individuals of varying opinions and backgrounds. 
 
4.1  Networking 
Within the DBMS class and within the profession, interaction with organisations like NEQAS, 
Leslie Brent Laboratory, Red Cell Immunology Reference Laboratory NHSBT Colindale, 
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Imperial College Healthcare NHS Trust, Bio-Rad and Ortho Clinical Diagnostics, academic 
staff from other Universities, Renal and Haematology consultants.  
This has helped me to establish a network of communication with these individuals and 
organisations and I can confidently draw upon these relationships in future projects or 
discussions. Through these networks, I have been able to acquire a vast amount of 
knowledge ranging from clinical to laboratory and manufacturing processes. 
Working with other students within the class gave me an appreciation of the interaction 
between different professions within health sciences and how evidence-based approach in 
the disciplines is essential in the development of patient care. 
 
4.2  Designing a method from scratch 
Designing the Indirect ELISA method for the measurement of ABO IgG antibody subclasses 
in ABOiRTx was a challenge as this was somewhat outside my area of expertise i.e. Blood 
Transfusion where ELISAs are not routinely used, let alone designed. However, with 
guidance and support, I managed to design and optimise the test. In this exercise I learnt how 
to formulate ideas for new technologies and be able to bring them to life. In this process, I 
learnt to interact with other scientists from research laboratories and share ideas and 
resources. I also learnt how to adapt to an unfamiliar scientific field. Designing the ELISA 
method was a major undertaking as not many groups have looked into this are with respect 
to ABOiRTx.  
4.3 Annual Reviews 
I found annual reviews very useful as I always received constructive ideas and comments 
from assessors and from other students.  
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Reviews always kept me on track and provided me with new insights into my area of study 
and gave me a chance to review some of my colleagues’ work as well and share ideas. 
Interacting with other professionals helped in cultivating confidence. 
4.4 Constraints 
Time has always been a major constraint as there was a great need to effectively balance 
this resource between family, work, studying and social life. Competing priorities in all these 
areas helped me to learn time management. I cannot say I managed to master this, but I can 
confirm that that I did my best given the challenges I encountered. 
During one of my annual reviews, it was agreed that the initial plan to investigate antibody 
titres in ABOiRTx would not produce enough new information given the rate at which this field 
was moving. Therefore, it was suggested that in addition, IgG antibody subclasses should 
also be investigated. This meant that additional time and resources were needed. This 
happened at a time when I was changing jobs, which meant that the original arrangement to 
use the research facilities at my old workplace had to be reviewed and new resources 
procured. This took time but once a new arrangement was made, it meant travelling from my 
new workplace to the old research laboratory which now had limited access. 
Starting a job as a manager at one of the largest Red Cell Immunology Laboratories in the 
country made time management a huge challenge as there was not much time for studying 
or anything else, so I resorted to using travelling time on public transport to cover various 
aspect of my project. 
Due to all these pressures, I had to request for an extension which went a long way in helping 
me to put more work into the project until completion. Overall, I learnt a lot in time 
management, especially the aspect of using every available time to cover different concepts. 
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4.5  Professional review and development module 
The professional Review module covered in this Professional Doctorate programme 
presented me with opportunity to review my strength and weaknesses in a structured manner 
and to learn how to enhance the identified strengths and remedy the weaknesses. 
This module helped me set goals for the rest of the programme which were reviewed regularly 
with the supervisor and also annually at the appraisal meetings. 
4.6  Advanced Statistics and Research Methodology  
Covering Advanced Statistics and Research Methodology enabled me to understand different 
approaches to statistical analyses ranging from qualitative to quantitative methods. Although 
my area of study is mainly quantitative in nature but learning qualitative methods made it 
possible for me to understand studies that make use of these methods. In addition, this made 
it possible for me to be able to supervise other students in my workplace whose areas of 
study require qualitative methodologies. 
Notably, in my own study, establishing the most appropriate statistical method for comparing 
the 6-antibody titration method in the absence of a gold standard was quite major undertaking 
involving a few statisticians.  
This also meant that sample size determination was also a challenge as this type of 
calculation had no precedence in this field of titration where the data was not linear and 
therefore needed manipulation before any meaningful statistics could be applied. 
Knowledge of various statistical processes through the DBMS programme has made it 
possible for me to engage a local journal club which is also interested in the cultivation of 
evidence-based practice and continuous professional development. 
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4.7  Application of experience and results from this study 
My project in ABO incompatible renal transplantation made it possible for the Hammersmith 
Hospital laboratory to gain knowledge and experience in ABO incompatible renal 
transplantation in terms of ABO antibody titration techniques and therapeutic plasma 
exchange.  
It has made it possible for antibody titration to be available for both ABOiRTx and other 
purposes like ABOi bone marrow transplants whenever required. 
Sharing knowledge on ABOiRTx and ABOcRTx has increased the laboratory’s expertise in 
this field and this has made it worthwhile as Hammersmith Hospital has one of the largest 
renal units in Europe  
The results of this study will be shared with UK NEQAS ABOi antibody titration pilot exercise 
whose aim is to standardise the titration methodology for ABOi transplantation. The findings 
in this study will add to the body of information available to inform formulation of guidelines.  
4.8 Teaching university students and training laboratory staff 
As Imperial College NHS Trust is a major teaching hospital and has one of the largest Renal 
units in Europe, I had the opportunity to use the knowledge and expertise that I gained through 
the Professional Doctorate to teach other members of staff or directly apply the knowledge. I 
had the opportunity to be part of a team of Training Officers who devised and harmonised a 
functional training system across 4 hospital sites. Through the DBMS programme I managed 
to successfully supervise 3 MSc students, 4 Specialist portfolio students while carrying out 
routine training of staff in the laboratory. 
I was also involved in teaching practical aspects of Blood Group Serology to Imperial College 
BSc students. I managed to use the Learning models learnt in my first year DBMS.  
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The feedback from most students was very encouraging and the teaching made it possible 
for most of them to understand all other theoretical aspects they were learning in their 
Transfusion module. 
4.9 Publications 
I have not had a chance to publish any journal article during the course of this programme 
although plans were there to do so. However, plans are still there to publish 2 papers from 
this thesis and the proposed titles are: 
 ABO Antibody titration methodologies against renal transplant outcome 
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